<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Death Dis</journal-id><journal-id journal-id-type="iso-abbrev">Cell Death Dis</journal-id><journal-title-group><journal-title>Cell Death &#x00026; Disease</journal-title></journal-title-group><issn pub-type="epub">2041-4889</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39890782</article-id><article-id pub-id-type="pmc">PMC11785747</article-id><article-id pub-id-type="publisher-id">7359</article-id><article-id pub-id-type="doi">10.1038/s41419-025-07359-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Histone lactylation promotes multidrug resistance in hepatocellular carcinoma by forming a positive feedback loop with PTEN</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zeng</surname><given-names>Yuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Jiang</surname><given-names>Haoran</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Zhoufeng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xiangting</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cai</surname><given-names>Weimin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zeng</surname><given-names>Xianjie</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Peipei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>lin</surname><given-names>Rong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Huilin</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Yuanhang</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Ying</surname><given-names>Huiya</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Ruoru</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0009-0007-3723-933X</contrib-id><name><surname>Wu</surname><given-names>Xiao</given-names></name><address><email>wuxiao@wmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5321-7228</contrib-id><name><surname>Yu</surname><given-names>Fujun</given-names></name><address><email>yufujun@wmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03cyvdv85</institution-id><institution-id institution-id-type="GRID">grid.414906.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1808 0918</institution-id><institution>Department of Gastroenterology, </institution><institution>the First Affiliated Hospital of Wenzhou Medical University, </institution></institution-wrap>Wenzhou, Zhejiang China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03cyvdv85</institution-id><institution-id institution-id-type="GRID">grid.414906.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1808 0918</institution-id><institution>Department of Radiation Oncology, </institution><institution>the First Affiliated Hospital of Wenzhou Medical University, </institution></institution-wrap>Wenzhou, Zhejiang China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03cyvdv85</institution-id><institution-id institution-id-type="GRID">grid.414906.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1808 0918</institution-id><institution>Department of Urology, </institution><institution>the First Affiliated Hospital of Wenzhou Medical University, </institution></institution-wrap>Wenzhou, Zhejiang China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/050s6ns64</institution-id><institution-id institution-id-type="GRID">grid.256112.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1797 9307</institution-id><institution>School of Pharmaceutical Science, </institution><institution>Fujian Medical University, </institution></institution-wrap>Fujian, China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00rd5t069</institution-id><institution-id institution-id-type="GRID">grid.268099.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0348 3990</institution-id><institution>The First Clinical Medical College, </institution><institution>Wenzhou Medical University, </institution></institution-wrap>Wenzhou, Zhejiang China </aff></contrib-group><pub-date pub-type="epub"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>16</volume><issue>1</issue><elocation-id>59</elocation-id><history><date date-type="received"><day>14</day><month>3</month><year>2024</year></date><date date-type="rev-recd"><day>21</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>16</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">FOLFOX (5-fluorouracil, oxaliplatin, folinic acid) is a standard treatment for hepatocellular carcinoma, but its efficacy is often limited by drug resistance, the underlying mechanisms of which remain unclear. In this study, oxaliplatin (OXA)- and 5-fluorouracil (5-Fu)-resistant hepatocellular carcinoma cell lines were established, and enhanced glycolytic activity was identified in resistant cells. Inhibiting glycolysis effectively suppressed the malignant behavior of both OXA- and 5-Fu-resistant cells. Mechanistically, active glycolysis induced elevated levels of lactylation, predominantly histone lactylation, with H3K14la playing a key role in regulating gene expression. The ubiquitin E3 ligase NEDD4 was identified as a downstream target of H3K14la. Furthermore, NEDD4, regulated by histone lactylation, interacted with PTEN to mediate its ubiquitination and subsequent degradation. The downregulation of PTEN formed a positive feedback loop, further driving the malignant progression of OXA- and 5-Fu-resistant cells. This study elucidates a shared mechanism underlying OXA and 5-Fu resistance in hepatocellular carcinoma and highlights a promising therapeutic target for overcoming clinical chemotherapy resistance.</p><p id="Par2">
<graphic position="anchor" xlink:href="41419_2025_7359_Figa_HTML" id="d33e306"/>
</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Cancer metabolism</kwd><kwd>Gastrointestinal cancer</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100004731</institution-id><institution>Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation)</institution></institution-wrap></funding-source><award-id>LY23H030003</award-id><principal-award-recipient><name><surname>Yu</surname><given-names>Fujun</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100008856</institution-id><institution>Department of Health of Zhejiang Province</institution></institution-wrap></funding-source><award-id>2024KY126</award-id><principal-award-recipient><name><surname>Yu</surname><given-names>Fujun</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100007194</institution-id><institution>Wenzhou Municipal Science and Technology Bureau (Wenzhou Municipal Sci - Tech Bureau)</institution></institution-wrap></funding-source><award-id>Y20220024</award-id><principal-award-recipient><name><surname>Yu</surname><given-names>Fujun</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100010909</institution-id><institution>National Science Foundation of China | Young Scientists Fund</institution></institution-wrap></funding-source><award-id>82300668</award-id><principal-award-recipient><name><surname>Yu</surname><given-names>Fujun</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Associazione Differenziamento e Morte Cellulare ADMC 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par3">Liver cancer is one of the leading causes of cancer-related death worldwide, and hepatocellular carcinoma (HCC) is the most prevalent type of primary liver cancer and the third leading cause of cancer-related mortality according to recent statistics [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin (OXA), fluorouracil (5-Fu), and leucovorin (FOLFOX) has been widely used in HCC patients [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. However, its effectiveness is limited, largely due to resistance [<xref ref-type="bibr" rid="CR5">5</xref>]. Therefore, identifying the molecular mechanisms of OXA and 5-Fu resistance is a prerequisite for improving the prognosis of patients with HCC [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par4">The Warburg effect was originally described as an increase in lactate production in cancer, and it has been confirmed to be associated with various malignant behaviors in HCC [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. In recent years, lactate-derived histone lysine lactylation has been proven to be a novel epigenetic modification and demonstrated to directly increase gene transcription within chromatin [<xref ref-type="bibr" rid="CR9">9</xref>]. Studies have shown that histone or nonhistone lactylation plays a role in melanoma [<xref ref-type="bibr" rid="CR10">10</xref>], colon cancer [<xref ref-type="bibr" rid="CR11">11</xref>] and pancreatic ductal adenocarcinoma [<xref ref-type="bibr" rid="CR12">12</xref>] by regulating m6A modification, cellular immunity and oncogene expression. Although the regulation of lactylation has been observed in HCC, the precise molecular mechanism underlying its role in OXA- and 5-Fu-resistance remains unclear.</p><p id="Par5">Neuronal precursor cell-expressed developmentally downregulated 4 (NEDD4) is a significant member of the HECT domain E3 ligase family in eukaryotes [<xref ref-type="bibr" rid="CR13">13</xref>], and plays a key role in various cellular processes through ubiquitination-mediated degradation of various substrates [<xref ref-type="bibr" rid="CR14">14</xref>]. To date, numerous studies have reported the involvement of NEDD4 in the regulation of tumor proliferation [<xref ref-type="bibr" rid="CR15">15</xref>], metastasis [<xref ref-type="bibr" rid="CR16">16</xref>], and stemness [<xref ref-type="bibr" rid="CR17">17</xref>]. However, whether NEDD4 is also involved in the development of OXA- and 5-Fu-resistant HCC remains unclear.</p><p id="Par6">In this study, we found that histone lactylation regulated the expression of NEDD4, enhanced the degradation of the oncogene PTEN, promoted glycolysis and OXA/5-Fu resistance, and participated in other malignant behaviors of HCC.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Cell lines and culture conditions</title><p id="Par7">Human HCC-LM3 (Lm3) and Huh7 cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and cultured in DMEM (Gibco, #11995040, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, #16140089, USA) and 1% penicillin/streptomycin (NCM Biotech, #C40050, China). The cells were incubated at 37&#x02009;&#x000b0;C in a CO<sub>2</sub> incubator with 5% CO<sub>2</sub>. All cells were STR authenticated and free from mycoplasma contamination before use.</p></sec><sec id="Sec4"><title>Generation of OXA- and 5-Fu-resistant cells</title><p id="Par8">Both OXA and 5-Fu were purchased from Macklin, China (61825-94-3, 51-21-8). OXA-resistant cells were generated as described previously [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], Briefly, Lm3 and Huh7 cells were grown to 60&#x02013;70% confluence, harvested with trypsin, and seeded in T25 cell culture flasks. After 24&#x02009;h, the medium was replaced with DMEM containing 10% FBS and 1&#x02009;&#x003bc;M OXA. After 48&#x02009;h, the medium was changed and drug treatment was terminated. After 24&#x02009;h of recovery and when the surviving cell population reached 80% confluence, cells were passaged and exposed to 1&#x02009;&#x003bc;M OXA for another 48&#x02009;h. The above steps were repeated for 6 cycles with 2, 4, 6, 8, or 10&#x02009;&#x003bc;M OXA for Lm3 cells and 8 cycles with 2, 4, 6, 8, 10, 20, or 25&#x02009;&#x003bc;M OXA for Huh7cells. After the cells developed stable resistance to OXA, they were designated Lm3-Res and Huh7-Res cells.</p><p id="Par9">To generate 5-Fu-resistant HCC cells [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>], Lm3 and Huh7 cells were cultured to 60&#x02013;70% confluence, digested with trypsin, and inoculated into T25 cell culture flasks. After 24&#x02009;h, the medium was replaced with DMEM containing 10% FBS and 5&#x02009;&#x003bc;M 5-Fu. After one week of culture, the drug was discontinued. Once the surviving cells resumed exponential growth after being relieved of 5-Fu pressure, they were passaged upon reaching 80% confluence, and then treated with 10&#x02009;&#x003bc;M 5-Fu for one week. Lm3 cells were treated with 10, 20, 40, or 60&#x02009;&#x003bc;M 5-Fu for five cycles, and Huh7 cells were treated with 10, 20, 40, 60, 80, or 100&#x02009;&#x003bc;M 5-Fu for seven cycles. When the cells developed stable resistance to 5-Fu, they were designated Lm3-Res and Huh7-Res cells.</p><p id="Par10">The resistant cells were frozen in liquid nitrogen, recovered after three passages, and their biological characteristics were analyzed in subsequent experiments. One week before the experiment, OXA- and 5-Fu-resistant cells were cultured in media without OXA or 5-Fu. All experiments were performed with exponentially growing cells, and each experiment was conducted with three biological replicates of the same resistant cell line.</p></sec><sec id="Sec5"><title>Establishment of the in vivo nude mouse model</title><p id="Par11">Twenty 4-week-old male and twenty 4-week-old female BALB/c nude mice (obtained from the Animal Experimental Center of the First Affiliated Hospital of Wenzhou Medical University) were housed in a pathogen-free environment and randomly assigned to one of four groups.</p><p id="Par12">A mouse tumor model was established via subcutaneous injection. After randomization, 1&#x02009;&#x000d7;&#x02009;10<sup>6</sup> OXA-resistant Lm3 OE-NEDD4 or OE-NC cells were injected subcutaneously. Seven days later, dimethylformamide, OXA (5&#x02009;mg/kg) and oxamate (750&#x02009;mg/kg) were intraperitoneally injected weekly. The tumor diameter was recorded every 7 days using a Vernier calliper, and the tumor volume was calculated using the following formula: volume (mm<sup>3</sup>)&#x02009;=&#x02009;0.5&#x02009;&#x000d7;&#x02009;width<sup>2</sup>&#x02009;&#x000d7;&#x02009;length. After 35 days, the mice were euthanized by CO<sub>2</sub> asphyxiation. The transplanted tumors were then excised and weighed. After euthanasia, gross images were taken. Some tissues were paraffin embedded and sliced into sections for immunofluorescence detection, some were used for protein extraction for western blot analysis, and the remaining tissues were stored at &#x02212;80&#x02009;&#x000b0;C for future use.</p><p id="Par13">The animal experiments were authorized by the Institutional Animal Care and Use Committee of the Animal Experiment Center at the First Affiliated Hospital of Wenzhou Medical University (WYYY-AEC-2022-029).</p></sec><sec id="Sec6"><title>Quantitative real-time polymerase chain reaction (qRT&#x02012;PCR)</title><p id="Par14">Total RNA was extracted from the cells using TRIzol reagent (Takara Biotech Co., Ltd.). The concentration of the extracted RNA was measured with a NanoDrop spectrophotometer (Thermo Fisher Scientific). Next, the RNA was reverse transcribed into complementary DNA (cDNA) using the PrimeScript RT Kit (Takara Biotech Co., Ltd.), following the manufacturer&#x02019;s instructions. The cDNA was then used to perform RT-qPCR with the CellAmp&#x02122; Direct TB Green&#x000ae; qRT&#x02012;PCR Kit (Takara Biotech Co., Ltd.). Gene expression levels were analyzed using the &#x00394;&#x00394;CT method and normalized to the <italic>&#x003b2;-actin</italic> mRNA levels in the cells. The primers used are listed in Supplementary Table <xref rid="MOESM3" ref-type="media">1</xref>.</p></sec><sec id="Sec7"><title>Western blots</title><p id="Par15">Total protein from tumor tissues and cells was extracted using cold RIPA lysis buffer (Solarbio, China) supplemented with a phosphatase inhibitor cocktail (GlpBio, USA) and PMSF (Beyotime, China). The protein concentration was measured with a BCA assay (Beyotime, China), and 20&#x02009;&#x003bc;g of total protein was used for immunoblotting. The protein lysates were separated by 12.5% SDS&#x02012;PAGE and transferred to a PVDF membrane with a pore size of 0.22&#x02009;&#x000b5;M (Millipore, Massachusetts, USA). The membrane was blocked for 20&#x02009;min with fast blocking buffer (Beyotime, Shanghai, China). Proportionally diluted antibodies were then incubated overnight. The membrane was washed three times with Tris buffer containing Tween solution (TBST: 50&#x02009;mmol/L Tris-HCl, pH 8.0, 150&#x02009;mmol/L NaCl, and 0.1% Tween-20), incubated with HRP-IgG antibody at room temperature for 2&#x02009;h, and washed again with TBST. The ECL signal was visualized using an Omni-ECL&#x02122; Enhanced Photochemiluminescence Kit (Epizyme Biomedical Technology, #SQ101, China). Protein intensity was analyzed using ImageJ software. Protein expression levels were normalized first to &#x003b2;-actin as the internal reference, and then to the control group to calculate the relative expression levels. The antibodies used in this study are listed in Supplementary Table <xref rid="MOESM3" ref-type="media">2</xref>.</p></sec><sec id="Sec8"><title>Cell viability assay</title><p id="Par16">Lm3, Huh7, Lm3-Res, and Huh7-Res cells were seeded into 96-well plates at a density of 5000 cells per well and incubated overnight. All CCK8 experiments were performed in triplicate and repeated three times. To measure the IC50 of 5-Fu, concentrations of 0, 10, 20, 40, 80, or 150&#x02009;&#x003bc;M 5-Fu were applied to the cells for 24&#x02009;h. Similarly, to determine the IC50 of OXA, OXA at concentrations of 0, 5, 10, 20, 40, or 80&#x02009;&#x003bc;M were applied to the cells for 24&#x02009;h, and 10&#x02009;&#x003bc;L of Cell Counting Kit 8 solution (CCK8, MedChemExpress, USA) was added to each well for 2&#x02009;h. The absorbance of each well was quantified at 450&#x02009;nm using a microplate reader (Bio-Tek, USA).</p></sec><sec id="Sec9"><title>Immunofluorescence assay</title><p id="Par17">For immunofluorescence, the cells were fixed with 4% paraformaldehyde and permeabilized with 0.5% Triton X-100. The cells and dewaxed tumor tissue sections were incubated with primary antibodies overnight in a humidified chamber at 4&#x02009;&#x000b0;C. Subsequently, the cells and tissue sections were incubated with fluorescein-labeled secondary antibodies according to the manufacturer&#x02019;s instructions, followed by incubation with DAPI (Biosharp, #BL520B, China), and the coverslip were sealed with nail polish. Fluorescence images were obtained using a fluorescence microscope (Leica, DM6 B, 40&#x000d7; objective), a confocal microscope (Leica, STELLARIS 5, 100x objective), and filters appropriate for the wavelengths used. The filter cube set included DAPI (EX 350/50, DC 400, EM 460/50), L5 (EX 480/40, DC 505, EM 527/30), and N21 (EX 538/46, DC 580, EM LP 590) (Leica, Germany). Using random field selection and sample blinding, ten images were captured for each sample. Representative fields of view were then selected for presentation.</p><p id="Par18">Immunofluorescence colocalization was performed using the &#x0201c;Coloc2&#x0201d; module in ImageJ. Pearson&#x02019;s correlation coefficient (PCC) was calculated; the closer the PCC is to 1, the stronger the colocalization. For cell fluorescence colocalization, individual cell ROIs were selected for Pearson&#x02019;s analysis, while for tissue fluorescence, the entire field of view was used for analysis [<xref ref-type="bibr" rid="CR22">22</xref>]. Approximately 500 cells were selected for quantification in each sample and the average value was taken. A total of three biological replicates were quantified. The antibodies used in this study are listed in Supplementary Table <xref rid="MOESM3" ref-type="media">2</xref>.</p></sec><sec id="Sec10"><title>Measurement of ROS levels</title><p id="Par19">Intracellular reactive oxygen species (ROS) levels were measured using an ROS detection kit (Beyotime, Shanghai, China) according to the manufacturer&#x02019;s instructions. The cells were digested with trypsin, resuspended, incubated with 10&#x02009;mM 2,7-dichlorofluorescein diacetate (DCFH-DA) at 37&#x02009;&#x000b0;C for 10&#x02009;min, washed three times with serum-free DMEM, and finally analyzed using a flow cytometer (Beckman Coulter). The results were analyzed using FlowJo V10 software. The gating strategy initially involved gating cells by the forward scatter area and side scatter area to remove debris, followed by gating cells by the forwards scatter area and the forwards scatter height to exclude doublets.</p></sec><sec id="Sec11"><title>Transwell assay</title><p id="Par20">Transwell migration assays were performed by seeding 2&#x02009;&#x000d7;&#x02009;10<sup>4</sup> cells with 200&#x02009;&#x003bc;L of serum-free DMEM into the upper chamber of a Transwell system (Corning, USA), and the lower chamber contained 600&#x02009;&#x003bc;L of DMEM supplemented with 10% FBS. After 48&#x02009;h of culture, all cells on the upper surface of the membrane were removed, and the cells on the lower surface were fixed and stained with crystal violet (Beyotime, Shanghai, China). Briefly, the bottoms of the Transwell were fixed by immersion in 4% paraformaldehyde for 20&#x02009;min, followed by immersion in crystal violet dye for 10&#x02009;min, and then washing with PBS solution on a shaker for 15&#x02009;min&#x02009;&#x000d7;&#x02009;3. After natural air drying, images were taken using an inverted phase contrast microscope (Olympus, Tokyo, Japan). Ten fields of view were randomly selected for each sample for quantitative analysis, and the average value was taken. A total of three biological replicates were performed for quantitative analysis. Representative images of the lower surface were quantified using ImageJ.</p></sec><sec id="Sec12"><title>Statistical analyses</title><p id="Par21">The results were imported into GraphPad Prism 8.0.2 software for analysis. Data comparisons between two groups were performed using the Student&#x02019;s <italic>t</italic> test, and comparisons of multiple groups were analyzed using the one-way analysis of variance (ANOVA) followed by Tukey&#x02019;s post hoc test. <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant. (*<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01; ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, ns: not significance.) More methods have been provided in the <xref rid="MOESM2" ref-type="media">Supplementary Methods</xref>.</p></sec></sec><sec id="Sec13" sec-type="results"><title>Results</title><sec id="Sec14"><title>Increased histone lactylation in OXA-resistant HCC cells</title><p id="Par22">To elucidate the underlying mechanism of OXA resistance, we established OXA-resistant cell lines. The results of the CCK8 assay indicated that the IC50 of the Lm3 OXA-resistant cell line changed from 6.24&#x02009;&#x003bc;M in the sensitive strain (Lm3-Ctrl) to 17.94&#x02009;&#x003bc;M in the resistant strain (Lm3-Res). Similarly, in Huh7 cells, the IC50 increased from 10.16&#x02009;&#x003bc;M (Huh7-Ctrl) to 30.19&#x02009;&#x003bc;M (Huh7-Res) (Fig. <xref rid="Fig1" ref-type="fig">1A, B</xref>). Numerous studies have demonstrated a close correlation between active aerobic glycolysis, lactylation and drug resistance in tumor cells [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. The results of the qRT&#x02012;PCR analysis showed that the mRNA levels of enzymes related to glycolysis were significantly greater in OXA-resistant cells (Res) than in OXA-sensitive cells (Ctrl) (Fig. <xref rid="Fig1" ref-type="fig">1C, D</xref>). Similarly, western blot analysis revealed significant elevation in the protein levels of PKM2, LDHA, HK2, and PFKFB3 (Fig. <xref rid="Fig1" ref-type="fig">1E&#x02013;G</xref>). Measurement of the lactate levels in both sensitive strains and OXA-resistant cells treated with OXA at similar concentrations (Lm3: 6&#x02009;&#x003bc;M, Huh7: 14&#x02009;&#x003bc;M) showed that OXA treatment increased intracellular lactate levels by 100% in sensitive cells (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S1.A</xref>). In contrast, the lactate levels in OXA-resistant cells were 400% to 500% higher than those in sensitive cells and showed no significant changes after OXA treatment (Fig. <xref rid="Fig1" ref-type="fig">1H</xref>), which is consistent with the findings of a previous study [<xref ref-type="bibr" rid="CR19">19</xref>]. These findings demonstrate that glycolysis was active in OXA-resistant HCC cells. Western blot analysis confirmed that the level of pan-lactylation (PKla) was higher in OXA-resistant cells than that in OXA-sensitive cells (Fig. <xref rid="Fig1" ref-type="fig">1I</xref>). Immunofluorescence revealed that lactylation modification primarily occurred in the nuclei of OXA-resistant cells, suggesting that lactylation modification of histones may be a primary modification within OXA-resistant cells (Fig. <xref rid="Fig1" ref-type="fig">1J, K</xref>). To further clarify the histone lactylation sites, we detected the changes of H3K15a and H3K14a proteins respectively. Notably, the H3K14a protein level was significantly increased in OXA-resistant cells, whereas the H3K15a protein level did not significantly change, suggesting that H3K14a may play an essential role in OXA resistance (Fig. <xref rid="Fig1" ref-type="fig">1I</xref>). Previous studies have shown that ROS levels and antioxidant enzyme activities are generally increased in drug-resistant cancer cells [<xref ref-type="bibr" rid="CR25">25</xref>]. Additionally, some studies have confirmed that complex regulatory mechanisms may exist between histone lactylation and ROS under different conditions [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>]. To further clarify whether the increase in histone lactylation in drug-resistant cells was mediated by ROS, we used flow cytometry to detect sensitive cells, sensitive cells treated with OXA alone, and OXA-resistant cells. The results showed that ROS were significantly increased in cells treated with OXA alone, but not obvious in OXA-resistant cell lines (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S1.B, C</xref>). This may be due to a more robust intracellular redox system during the drug resistance process [<xref ref-type="bibr" rid="CR25">25</xref>]. Additionally, when the ROS scavenger N-acetyl-L-cysteine (NAC) was used, we observed no significant change in H3K14la histone lactylation in drug-resistant cells (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S1.D, E</xref>). These findings suggest that ROS accumulation during the drug resistance process does not promote H3K14la expression, and the specific mechanism of increased histone lactylation in drug-resistant cells requires further investigation. These data indicate that a large portion of OXA-resistant cells are characterized by active glycolysis and lactylation modifications, which are likely the underlying mechanism of OXA resistance.<fig id="Fig1"><label>Fig. 1</label><caption><title>OXA-resistant HCC cells exhibit active histone lactylation.</title><p><bold>A</bold> IC50 values of OXA-sensitive (Ctrl) and OXA-resistant strains (Res) in Lm3 cells. (The dashed line represents the drug concentration at which 50% of cells survive.) <bold>B</bold> IC50 values of OXA-sensitive (Ctrl) and OXA-resistant strains (Res) in Huh7. (The dashed line represents the drug concentration at which 50% of cells survive.) <bold>C</bold>, <bold>D</bold> Glycolysis-related enzyme mRNA levels detected via qRT&#x02012;PCR in Lm3 and Huh7 cells (n&#x02009;=&#x02009;3). <bold>E</bold>&#x02013;<bold>G</bold> Glycolysis-related enzyme protein levels in Lm3 and Huh7 cells were detected via western blotting (n&#x02009;=&#x02009;3). <bold>H</bold> Intracellular lactate production occurs in OXA-sensitive (Ctrl) and OXA-resistant (Res) cells in Lm3 and Huh7, respectively (n&#x02009;=&#x02009;3). <bold>I</bold> Western blot analysis of PKla and histone lactylation protein levels in OXA-resistant cells. <bold>J</bold>, <bold>K</bold> Immunofluorescence confirmed the predominant intracellular localization of lactylation. Scale bar =&#x02009;10&#x02009;&#x000b5;m. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001.</p></caption><graphic xlink:href="41419_2025_7359_Fig1_HTML" id="d33e599"/></fig></p></sec><sec id="Sec15"><title>Inhibition of histone lactylation suppressed the progression of OXA-resistant cells</title><p id="Par23">To determine whether histone lactylation is involved in the molecular mechanisms of regulating OXA resistance, we employed various methods to reduce the level of intracellular histone lactylation (Fig. <xref rid="Fig2" ref-type="fig">2A</xref>). The production of intracellular lactate was significantly reduced in a dose-dependent manner after treatment with the nonmetabolizable glucose analogs 2-deoxy-d-glucose (2-DG), and oxamate, as well as si-LDHA and si-LDHB (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S2.A, B</xref>). Additionally, both the intracellular and histone lactylation levels were significantly reduced (Fig. <xref rid="Fig2" ref-type="fig">2B</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S2.C</xref>). To further elucidate the malignant behavior of OXA-resistant cells, we treated both OXA-sensitive and OXA-resistant cells with a low concentration (IC75) of OXA. All Lm3 and Huh7 cells were treated with 6&#x02009;&#x003bc;M and 14&#x02009;&#x003bc;M OXA, respectively. Transwell experiments revealed that migration of the resistant strain was not significantly inhibited by OXA compared with that of the sensitive strain. However, the number of migrating cells was significantly reduced after the addition of the histone lactylation inhibitor (Fig. <xref rid="Fig2" ref-type="fig">2C</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S2.D</xref>). The colony formation assay showed that OXA-resistant strains formed fewer colonies after inhibition of histone lactylation (Fig. <xref rid="Fig2" ref-type="fig">2D</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S2.E</xref>). Similar results were also observed in the EdU experiment (Fig. <xref rid="Fig2" ref-type="fig">2E</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S2.F</xref>). The western blot showed that compared with those of the sensitive strain, OXA had no effect on the expression levels of the EMT-related proteins E-cadherin, N-cadherin and vimentin in the resistant strain. However, the addition of oxamate significantly enhanced the effects of OXA on OXA-resistant strains and markedly reduced the expression levels of the abovementioned proteins. Similarly, comparable results were observed for the expression levels of the proliferation-related proteins PCNA and CyclinD1 (Fig. <xref rid="Fig2" ref-type="fig">2F</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S2.G</xref>). Finally, we conducted further investigations to explore whether histone lactylation is involved in the regulation of cell stemness. Immunofluorescence experiments demonstrated that the expression of CD44 and EpCAM proteins was effectively suppressed by oxamate in OXA-resistant strains (Fig. <xref rid="Fig2" ref-type="fig">2G&#x02013;H</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S3.A</xref>). Additionally, a sphere-formation assay demonstrated that inhibiting histone lactylation significantly reduced the cell spheroid size (Fig. <xref rid="Fig2" ref-type="fig">2I</xref>). In summary, histone lactylation may play a crucial role in regulating the proliferation, migration, stemness, and other malignant behaviors of OXA-resistant cells. Inhibiting histone lactylation may effectively increase the sensitivity to OXA chemotherapy, thus inhibiting tumor progression.<fig id="Fig2"><label>Fig. 2</label><caption><title>Targeting histone lactylation inhibits the malignant behavior of OXA-resistant cells.</title><p><bold>A</bold> Different inhibitors of the lactylation process. <bold>B</bold> Western blot analysis of PKla and histone lactylation in oxamate and 2-DG treated OXA-resistant cells (Lm3-Res and Huh7-Res). <bold>C</bold> Transwell assays identified OXA-sensitive (Ctrl) and OXA-resistant (Res) cell migration, Scale bar =&#x02009;200&#x02009;&#x000b5;m. <bold>D</bold> Colony formation experiments confirmed the proliferation of OXA-sensitive (Ctrl) and OXA -resistant (Res) cells. <bold>E</bold> Resistant cells were treated with OXA and the proliferation of sensitive and resistant cells was assayed with EdU, scale bar =&#x02009;100&#x02009;&#x000b5;m. <bold>F</bold> Western blot analysis revealed changes in the levels of EMT-related proteins and proliferation-related proteins in both sensitive and resistant cells. <bold>G</bold>, <bold>H</bold> Both sensitive and resistant cells were treated with OXA, and immunofluorescence was used to detect changes in the protein levels of the stemness-related proteins CD44 and EpCAM in Lm3 cells, scale bar =&#x02009;10&#x02009;&#x000b5;m. <bold>I</bold> Both sensitive and resistant cells were treated with OXA and a spheroid formation assay was performed to dectect tumor cell stemness, scale bar =&#x02009;20&#x02009;&#x000b5;m. Lm3- and Huh7-sensitive and -resistant cells were treated with 6&#x02009;&#x003bc;M and 14&#x02009;&#x003bc;M OXA, respectively. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001.</p></caption><graphic xlink:href="41419_2025_7359_Fig2_HTML" id="d33e699"/></fig></p></sec><sec id="Sec16"><title>Histone lactylation regulates ubiquitination in OXA-resistant strains</title><p id="Par24">To clarify the regulatory role of histone lactylation in OXA-resistant strains, we first performed chromatin immunoprecipitation followed by sequencing (ChIP-seq) using anti-H3K14la antibodies in OXA-resistant Lm3 cells, and then performed gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. The results showed that histone lactylation was mainly involved in regulating the intracellular ubiquitination process (Fig. <xref rid="Fig3" ref-type="fig">3A, B</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S3.B</xref>). In addition, the KEGG enrichment analysis suggested that histone lactylation may play a regulatory role through ubiquitination-mediated protein degradation (Fig. <xref rid="Fig3" ref-type="fig">3C</xref>). To further study how histone lactylation affects the ubiquitination process in OXA-resistant strains, we screened the related ubiquitin E3 ligase NEDD4 in the KEGG database (Fig. <xref rid="Fig3" ref-type="fig">3D</xref>). Previous studies have suggested that NEDD4 plays a key role in a variety of cellular processes through ubiquitination-mediated degradation of multiple substrates [<xref ref-type="bibr" rid="CR29">29</xref>]. To confirm whether the activation of NEDD4 transcription was dependent on H3K14la, we observed marked enrichment of the H3K14la signal specific to the promoter region of the NEDD4 gene (Fig. <xref rid="Fig3" ref-type="fig">3E</xref>). The base pair enrichment of the ChIP-seq promoter region is shown in Fig. <xref rid="Fig3" ref-type="fig">3F</xref>. Additionally, we used western blotting to detect the intracellular NEDD4 protein level, and found that the NEDD4 protein level remained unchanged in the sensitive strain treated with OXA alone, but was increased in the OXA-resistant strain, and decreased after protein lactylation in the inhibition group (Fig. <xref rid="Fig3" ref-type="fig">3G</xref>). Given that EP300 is the key enzyme for histone lactylation, we used oxamate, si-EP300 and a combination of the two to inhibit the intracellular histone lactylation levels in OXA-resistant cells. The result showed that the NEDD4 protein level was significantly reduced, whereas there was no statistically significant change in the protein level under the above treatments. Moreover, adding additional lactate after EP300 silencing did not restore the protein level of NEDD4 (Fig. <xref rid="Fig3" ref-type="fig">3H</xref>). Similarly, the inhibition of intracellular lactylation levels by 2-DG and oxamate resulted in a concurrent reduction in overall intracellular ubiquitination levels (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S3.D</xref>). These data suggest that the expression of the E3 ubiquitin ligase NEDD4 in OXA-resistant strains is positively regulated by histone lactylation.<fig id="Fig3"><label>Fig. 3</label><caption><title>ChIP-Seq reveals the involvement of histone lactylation in modifying NEDD4 in OXA-resistant cells.</title><p><bold>A</bold>, <bold>B</bold> GO analysis confirmed that histone lactylation was involved in regulating cell function. <bold>C</bold>, <bold>D</bold> KEGG analysis confirmed that histone lactylation primarily regulated signaling pathways. <bold>E</bold> Integrative Genomics Viewer (IGV) trace of NEDD4 from ChIP-seq analysis. <bold>F</bold> Enriched promoter region bases. <bold>G</bold> NEDD4 protein levels were detected by western blotting (n&#x02009;=&#x02009;3). <bold>H</bold> NEDD4 protein levels were detected by western blotting after the addition of si-EP300, oxamate or lactate (n&#x02009;=&#x02009;3). *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001.</p></caption><graphic xlink:href="41419_2025_7359_Fig3_HTML" id="d33e779"/></fig></p></sec><sec id="Sec17"><title>Histone lactylation mediates malignant progression of OXA-resistant strains through NEDD4</title><p id="Par25">Many studies have shown that NEDD4 plays a significant role in the progression of breast cancer [<xref ref-type="bibr" rid="CR30">30</xref>], bladder cancer [<xref ref-type="bibr" rid="CR31">31</xref>], and lung cancer [<xref ref-type="bibr" rid="CR32">32</xref>]. In addition, the TCGA database shows that high expression of NEDD4 is associated with poor prognosis in patients with lung adenocarcinoma, multiple myeloma, and mesothelioma. However, the association between NEDD4 expression and patient prognosis in HCC remains unclear (Fig. <xref rid="Fig4" ref-type="fig">4A</xref>). Therefore, we verified the function of NEDD4 in HCC cells by silencing the expression of NEDD4 with siRNAs (si-NEDD4#1 and si-NEDD4#2). The EdU assay results showed that the proliferation of OXA-resistant cells was significantly reduced when NEDD4 was silenced, compared with that of control cells (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S3.E, F</xref>). Similar results were observed via western blotting, where the levels of the proliferation-related proteins PCNA and CyclinD1, as well as EMT-related proteins, were downregulated after NEDD4 silencing (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S3.G, H</xref>). Given that NEDD4 expression is regulated by H3K14la, we determined whether the tumor suppression induced by oxamate could be rescued by increasing NEDD4. After an OXA-resistant strain stably overexpressing NEDD4 was constructed using lentivirus and treated with OXA, we assessed alterations in cell proliferation and migration ability using EdU (Fig. <xref rid="Fig4" ref-type="fig">4B</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S4.A</xref>), colony formation (Fig. <xref rid="Fig4" ref-type="fig">4C</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S4.B</xref>), and Transwell assays (Fig. <xref rid="Fig4" ref-type="fig">4D</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S4.C</xref>). These results suggested that tumor behavior, which was suppressed by the inhibition of histone lactylation was effectively reversed after the overexpression of NEDD4. We subsequently observed alterations in the levels of proteins related to proliferation and EMT (Fig. <xref rid="Fig4" ref-type="fig">4E, F</xref>). The subsequent sphere-formation assay confirmed that the inhibition of cell stemness caused by histone lactylation inhibitors could be reversed by the overexpression of NEDD4 (Fig. <xref rid="Fig4" ref-type="fig">4G</xref>). Overall, our study found that the tumor suppressive effects of blocking histone lactylation could be hindered by OE-NEDD4, indicating that the tumor promotion effect mediated by histone lactylation was partly achieved through NEDD4.<fig id="Fig4"><label>Fig. 4</label><caption><title>Histone lactylation mediates OXA resistance through NEDD4.</title><p><bold>A</bold> Analysis of the TCGA database to investigate the correlation between NEDD4 expression and the prognosis of patients with various tumors. After OXA-resistant cells (Res) were treated with low-dose OXA, they were given oxamate or OE-NEDD4. Cell proliferation was detected via <bold>B</bold> EdU (scale bar =&#x02009;100&#x02009;&#x000b5;m) and <bold>C</bold> colony formation, <bold>D</bold> cell migration was detected via Transwell assays (scale bar =&#x02009;200&#x02009;&#x000b5;m), and <bold>G</bold> cell stemness was detected via spheroid formation experiments (scale bar =&#x02009;20&#x02009;&#x000b5;m). <bold>E</bold>, <bold>F</bold> Western blotting was used to determine the expression of EMT-related proteins and proliferation-related proteins in OXA-sensitive (Ctrl) and OXA-resistant (Res) cells (n&#x02009;=&#x02009;3). Lm3 and Huh7 OXA-resistant cells were treated with 6&#x02009;&#x003bc;M and 14&#x02009;&#x003bc;M OXA, respectively. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001.</p></caption><graphic xlink:href="41419_2025_7359_Fig4_HTML" id="d33e869"/></fig></p></sec><sec id="Sec18"><title>NEDD4-induced PTEN ubiquitination mediates OXA-resistance in HCC cells</title><p id="Par26">Next, we further clarified how histone lactylation regulated the drug resistance mechanism of HCC through NEDD4. NEDD4, an E3 ubiquitin ligase, participates in regulating the ubiquitin degradation process of numerous proteins [<xref ref-type="bibr" rid="CR33">33</xref>]. Numerous studies have shown that NEDD4 is involved in regulating the stability of PTEN [<xref ref-type="bibr" rid="CR34">34</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>]. Therefore, we investigated whether NEDD4 is also involved in mediating the ubiquitination and proteasomal degradation of PTEN in HCC. Western Blots showed that compared with that in the sensitive strain, the change in the PTEN protein level was not significant after treatment with OXA alone, whereas in the OXA-resistant strain, the PTEN protein level decreased and could be restored by oxamate (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S3.C</xref>). The immunofluorescence results indicated that the colocalization and binding of NEDD4 and PTEN in OXA-resistant strains were greater than those in sensitive strains, and this effect could be inhibited by histone lactylation inhibitors (Fig. <xref rid="Fig5" ref-type="fig">5A, B</xref>). Similar results were also observed in the Co-IP experiment (Fig. <xref rid="Fig5" ref-type="fig">5C</xref>). We further investigated the regulation of PTEN by the proteasome system. By employing the translation inhibitor cycloheximide (CHX) to inhibit intracellular protein translation, we observed a significant decrease in the half-life of the PTEN protein in the OXA-resistant strain compared with that of the control group. This phenomenon could also be blocked by histone lactylation inhibitors (Fig. <xref rid="Fig5" ref-type="fig">5D, E</xref>). The accumulation of PTEN in OXA-resistant cells was also significantly increased after treatment with a proteasome inhibitor (MG132) (Fig. <xref rid="Fig5" ref-type="fig">5F, G</xref>), indicating that PTEN in OXA-resistant cells is regulated mainly through the proteasome pathway. We further examined changes in PTEN ubiquitination levels, and found that the level of PTEN ubiquitination in OXA-resistant cells was significantly higher than that in OXA-sensitive cells. The overexpression of NEDD4 rescued the level of ubiquitination inhibited by oxamate (Fig. <xref rid="Fig5" ref-type="fig">5H</xref>) [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. These findings indicate that NEDD4 is involved in regulating the level of ubiquitinated PTEN in OXA-resistant cells. PTEN is one of the most frequently mutated or deleted genes in cancer [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Loss of PTEN influences important cellular processes that are critical to cancer progression, including changes in survival, proliferation, energy metabolism, and cell structure [<xref ref-type="bibr" rid="CR39">39</xref>]. PTEN has been found to interfere with tumor progression by inhibiting the PI3K/Akt/mTOR pathway [<xref ref-type="bibr" rid="CR41">41</xref>]. Western blot analysis revealed that the PI3K/Akt/mTOR pathway was significantly activated in OXA-resistant cells compared with that in sensitive cells. After inhibiting histone lactylation, the levels of intracellular <italic>p</italic>-AKT and <italic>p</italic>-mTOR proteins were subsequently reduced. However, overexpression of NEDD4 restored the above protein levels in cells (Fig. <xref rid="Fig5" ref-type="fig">5I, J</xref>). Additionally, our ChIP data revealed the presence of NEDD4L, another member of the NEDD4 family. Previous studies have shown that NEDD4L has a complex regulatory relationship with PTEN [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. To determine whether NEDD4L is also involved in the regulation of PTEN in OXA-resistant HCC, we used si-NEDD4L to silence NEDD4L expression in cells (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S5.A</xref>). We then examined the expression of PTEN and its downstream molecules. The results showed that PTEN protein levels did not change significantly after si-NEDD4L treatment, and the histone lactylation inhibitor continued to inhibit PTEN degradation even after NEDD4L was silenced (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S5.B</xref>). Collectively, these results confirmes that histone lactylation promotes resistance to OXA by upregulating NEDD4-mediated ubiquitination and degradation of PTEN, thereby activating the PI3K/Akt/mTOR signaling pathway.<fig id="Fig5"><label>Fig. 5</label><caption><title>NEDD4 mediates PTEN ubiquitination to induce OXA resistance.</title><p><bold>A</bold> Immunofluorescence confirmed the colocalization of NEDD4 and PTEN in OXA-sensitive (Ctrl) and OXA-resistant (Res) cells, scale bar&#x02009;=&#x02009;10&#x02009;&#x000b5;m. The X-axis represents the pixel intensity of NEDD4 (red), and the Y-axis represents the pixel intensity of PTEN (green). <bold>B</bold> Colocalization was quantified via ImageJ (n&#x02009;=&#x02009;3). <bold>C</bold> Co-IP confirmed that NEDD4 binds to PTEN in in OXA-sensitive (Ctrl) and OXA-resistant (Res) cells. <bold>D</bold>, <bold>E</bold> Western blotting was used to detect and quantify the half-life of PTEN after treatment with CHX alone. <bold>F</bold>, <bold>G</bold> Western blot analysis revealed changes in PTEN protein levels after treatment with MG132 alone. <bold>H</bold> Detection of NEDD4 binding and ubiquitination levels using western blotting after Co-IP with PTEN in OXA-sensitive (Ctrl) and OXA-resistant (Res) cells. <bold>I</bold>, <bold>J</bold> Western blot analysis of PTEN and AKT/mTOR protein levels (n&#x02009;=&#x02009;3). PCC Pearson&#x02019;s correlation coefficient *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001.</p></caption><graphic xlink:href="41419_2025_7359_Fig5_HTML" id="d33e994"/></fig></p></sec><sec id="Sec19"><title>Histone lactylation mediates 5-Fu resistance through NEDD4-induced PTEN ubiquitination</title><p id="Par27">Several recent studies have shown that transarterial infusion (TAI) chemotherapy with the FOLFOX regimen alone results in improved survival in advanced HCC patients [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. However, the effectiveness of FOLFOX combination chemotherapy is greatly limited by drug resistance. Although drug resistance is common in colorectal cancer, a similar phenomenon also exists in HCC [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. Therefore, we further explored whether there is a similar mechanism for resistance to 5-Fu. We constructed a 5-Fu resistant cell strain, in which the IC50 of Lm3-resistant cells increased from 27.64&#x02009;&#x003bc;M to 70.09&#x02009;&#x003bc;M in the sensitive strain, and the IC50 in the Huh7-resistant strain increased from 43.41&#x02009;&#x003bc;M to 116.2&#x02009;&#x003bc;M (Fig. <xref rid="Fig6" ref-type="fig">6A</xref>). The above results suggest that the 5-Fu resistant strain was successfully constructed. Similarly, active lactate production was also demonstrated in 5-Fu-resistant cell lines and could be inhibited by oxamate (Fig. <xref rid="Fig6" ref-type="fig">6B</xref>). Western blot analysis revealed that lactylation levels and H3K14la levels were significantly increased in 5-Fu-resistant cells (Fig. <xref rid="Fig6" ref-type="fig">6C</xref>). Similarly, we assessed global ubiquitination levels in 5-Fu-resistant cells, where the elevated ubiquitination observed in these resistant cells was effectively reduced by oxamate treatment (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S5.C</xref>). Changes in NEDD4 protein levels were detected using a lactylation inhibitor, si-EP300 and combination of two. The results showed that both lactylation inhibitors and si-EP300 downregulated NEDD4 protein levels, although the degree of downregulation was not statistically significant. Exogenous addition of lactate after si-EP300 transfection did not restore NEDD4 protein levels (Fig. <xref rid="Fig6" ref-type="fig">6D</xref>). We subsequently detected the protein levels of NEDD4 and PTEN, and found that the NEDD4 level was increased and the PTEN level was decreased in 5-Fu-resistant cell lines (Fig. <xref rid="Fig6" ref-type="fig">6E</xref>). Immunofluorescence indicated a strong increase in the colocalization of NEDD4 and PTEN in 5-Fu-resistant cell lines (Fig. <xref rid="Fig6" ref-type="fig">6F, G</xref>). Additionally, Co-IP experiments also demonstrated an increase in the binding of PTEN to NEDD4 in 5-Fu-resistant cell lines, along with an increase in the level of PTEN ubiquitination (Fig. <xref rid="Fig6" ref-type="fig">6H</xref>). To further confirm that NEDD4 mediates the ubiquitination and degradation of PTEN, we introduced Flag-NEDD4, Myc-PTEN, and HA-Ub into HEK293T cells for ubiquitination experiments. As expected, the introduction of NEDD4 significantly increased PTEN ubiquitination (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S6.A</xref>). These findings indicate that histone lactylation participated in the regulation of NEDD4-mediated ubiquitination and degradation of PTEN in HCC cells, playing a significant role in the development of resistance to 5-Fu.<fig id="Fig6"><label>Fig. 6</label><caption><title>The histone lactylation/NEDD4/PTEN axis plays an important role in 5-Fu-resistant cells.</title><p><bold>A</bold> IC50 values of 5-Fu-sensitive (Ctrl) and 5-Fu-resistant strains (Res) in Lm3 and Huh7 cells. (The dashed line represents the drug concentration at which 50% of cells survive.) <bold>B</bold> Intracellular lactate production in 5-Fu-sensitive (Ctrl) and 5-Fu-resistant (Res) cells. (The dashed line represents the drug concentration at which 50% of cells survive.) <bold>C</bold> Western blot analysis of changes in PKla and H3K14la protein levels after oxamate treatment. <bold>D</bold> Changes in NEDD4 protein levels in 5-Fu-resistant cells (Res) under si-EP300, oxamate, and lactate treatments. <bold>E</bold> PTEN and NEDD4 protein levels were detected by western blotting. <bold>F</bold> Immunofluorescence confirmed the increased colocalization of PTEN and NEDD4 in 5-Fu-resistant cells, scale bar =&#x02009;10&#x02009;&#x000b5;m. The X-axis represents the pixel intensity of NEDD4 (red), and the Y-axis represents the pixel intensity of PTEN (green). <bold>G</bold> Colocalization was quantified using ImageJ (n&#x02009;=&#x02009;3). <bold>H</bold> Detection of PTEN ubiquitination levels after Co-IP with PTEN in 5-Fu-sensitive (Ctrl) and resistant (Res) cells. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001.</p></caption><graphic xlink:href="41419_2025_7359_Fig6_HTML" id="d33e1084"/></fig></p><p id="Par28">In our study, we demonstrated that NEDD4 is highly expressed in cells resistant to 5-FU and OXA, and that OE-NEDD4 can partially reverse the inhibition of lactylation. However, it remains unclear whether HCC cells that naturally overexpress NEDD4 are inherently more resistant. Using the CCK-8 assay, we assessed changes in the IC50 values of OXA and 5-FU in both normal cells and cells overexpressing NEDD4. Overexpression of NEDD4 led to an increase in the IC50 of OXA from 6.096&#x02009;&#x003bc;M to 8.883&#x02009;&#x003bc;M in Lm3 cells and from 10.97&#x02009;&#x003bc;M to 17.26&#x02009;&#x003bc;M in Huh7 cells, as well as an increase in the IC50 of 5-FU from 27.44&#x02009;&#x003bc;M to 37.75&#x02009;&#x003bc;M in Lm3 cells and from 40.12&#x02009;&#x003bc;M to 56.08&#x02009;&#x003bc;M in Huh7 cells (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S6.B</xref>). Additionally, we analyzed the TCGA database to examine the relationship between NEDD4 expression and the IC50s of gemcitabine, cisplatin, sorafenib, and docetaxel. The results indicated that higher NEDD4 expression correlated with a decrease in the IC50 values of sorafenib, but an increase in the IC50 values of cisplatin and docetaxel. In addition, the IC50 change of gemcitabine was not significantly related to the expression of NEDD4 (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S6.C</xref>). In general, whether HCC that naturally overexpresses NEDD4 is prone to drug resistance appears to depend on the specific drug. However, this conclusion requires further validation through clinical data.</p></sec><sec id="Sec20"><title>Glycolysis/H3K14la/PTEN forms a positive feedback loop in OXA and 5-Fu resistant HCC</title><p id="Par29">Previous studies have shown that PTEN plays an important role in regulating intracellular glycolysis [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. For example, <italic>PKM2</italic> transcription is regulated by PTEN/mTOR [<xref ref-type="bibr" rid="CR50">50</xref>], and PTEN also reduces the stability of PFKFB3 [<xref ref-type="bibr" rid="CR51">51</xref>]. To investigate whether PTEN also regulates glycolysis and influences H3K14la to establish a positive feedback loop in OXA and 5-Fu resistant cells, we overexpressed PTEN in OXA- and 5-Fu-resistant cells (OE-PTEN) (Fig. <xref rid="Fig7" ref-type="fig">7A</xref>) and found that PTEN overexpression significantly reduced the intracellular lactate levels (Fig. <xref rid="Fig7" ref-type="fig">7B</xref>). qRT&#x02012;PCR analysis revealed that the mRNA levels of glycolysis-related genes <italic>PKM2</italic>, <italic>PFKFB3</italic>, <italic>LDHA</italic>, and <italic>HK2</italic> decreased to varying degrees (Fig. <xref rid="Fig7" ref-type="fig">7C, D</xref>). Western blot assays showed that the protein levels of the key glycolytic enzymes PKM2, PFKFB3, LDHA and HK2 were significantly reduced (Fig. <xref rid="Fig7" ref-type="fig">7E</xref>). Importantly, the levels of PKla, H3K14la and NEDD4 also decreased dramatically (Fig. <xref rid="Fig7" ref-type="fig">7F</xref>). Overall, restoring PTEN levels in OXA- and 5-Fu-resistant cells significantly reduced glycolysis levels and disrupted the glycolysis/H3K14la/PTEN positive feedback loop.<fig id="Fig7"><label>Fig. 7</label><caption><title>Overexpression of PTEN blocks the glycolysis/H3K14la/PTEN positive feedback loop in OXA and 5-Fu resistant HCC.</title><p><bold>A</bold> qRT&#x02012;PCR was used to verify the successful induction of PTEN overexpression of PTEN overexpression in OXA- and 5-Fu -resistant cell lines (Res) (n&#x02009;=&#x02009;3). <bold>B</bold> Measurement of lactate levels in resistant cells overexpressing PTEN (n&#x02009;=&#x02009;3). <bold>C</bold> qRT&#x02012;PCR confirmed altered levels of the glycolysis-related genes <italic>PKM2, PFKFB3, LDHA</italic> and <italic>HK2</italic> after OE-PTEN treatment in 5-Fu resistant cells (Res) (n&#x02009;=&#x02009;3). <bold>D</bold> qRT&#x02012;PCR confirmed altered levels of the glycolysis-related genes <italic>PKM2, PFKFB3, LDHA</italic> and <italic>HK2</italic> after OE-PTEN treatment in OXA resistant cells (Res) (n&#x02009;=&#x02009;3). <bold>E</bold> The protein levels of PKM2, PFKFB3, LDHA and HK2, which are key enzymes involved in the glycolytic process, were assayed after OE-PTEN treatment in resistant cells. <bold>F</bold> After OE-PTEN treatment, western blotting was used to detect PKla, H3K14la and NEDD4 protein levels in resistant cells. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001.</p></caption><graphic xlink:href="41419_2025_7359_Fig7_HTML" id="d33e1192"/></fig></p></sec><sec id="Sec21"><title>Histone lactylation regulates OXA resistance via NEDD4/PTEN in vivo</title><p id="Par30">To investigate whether a similar mechanism of histone lactylation exists in vivo, OXA-resistant Lm3 cells were injected into male and female nude mice to establish a xenograft tumor model (Fig. <xref rid="Fig8" ref-type="fig">8A</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S7.A</xref>). Compared with OXA alone, the addition of the histone lactylation inhibitor oxamate significantly reduced the tumor volume. Conversely, the introduction of OE-NEDD4 increased the tumor volume accordingly (Fig. <xref rid="Fig8" ref-type="fig">8B, C</xref>). We subsequently detected changes in protein levels. The results suggested that OE-NEDD4 can significantly increase the levels of inhibited lactylation and histone lactylation (Fig. <xref rid="Fig8" ref-type="fig">8D, F</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S7.B</xref>). Immunofluorescence showed that NEDD4 colocalized with PTEN in vivo and was restored by NEDD4 overexpression after inhibition (Fig. <xref rid="Fig8" ref-type="fig">8E, G</xref>). Finally, similar results were also observed for the protein levels of NEDD4, PTEN, <italic>p</italic>-AKT, and <italic>p</italic>-mTOR in vivo (Fig. <xref rid="Fig8" ref-type="fig">8H, I</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">S7.C, D</xref>). These results demonstrate that the histone lactylation/NEDD4/PTEN axis plays an important regulatory role in OXA resistance in vivo and this regulatory role is not significantly related to gender.<fig id="Fig8"><label>Fig. 8</label><caption><title>In vivo validation of the role of the histone lactylation/NEDD4/PTEN axis in OXA resistance.</title><p><bold>A</bold> Gross nude mouse xenograft (n&#x02009;=&#x02009;5). <bold>B</bold> Quantification of tumor volume (n&#x02009;=&#x02009;10). <bold>C</bold> Tumor volume changed over time (n&#x02009;=&#x02009;10). <bold>D</bold> Western blot analysis of lactylation and histone lactylation levels in vivo. <bold>E</bold> Immunofluorescence detection and quantification of NEDD4 and PTEN colocalization in xenografts, scale bar =&#x02009;10&#x02009;&#x000b5;m. The X-axis represents the pixel intensity of NEDD4 (red), and the Y-axis represents the pixel intensity of PTEN (green). <bold>F</bold> Quantification of H3K14la protein levels (n&#x02009;=&#x02009;10). <bold>G</bold> Quantification of Pearson&#x02019;s correlation coefficient with immunofluorescence (n&#x02009;=&#x02009;3). <bold>H</bold>, <bold>I</bold> Western blot analysis revealed changes in the levels of proteins, such as NEDD4, PTEN, and mTOR (n&#x02009;=&#x02009;3). PCC Pearson&#x02019;s correlation coefficient *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001.</p></caption><graphic xlink:href="41419_2025_7359_Fig8_HTML" id="d33e1279"/></fig></p></sec></sec><sec id="Sec22" sec-type="discussion"><title>Discussion</title><p id="Par31">FOLFOX is widely recognized as an established treatment for HCC. Although combination therapy has been proven to improve therapeutic outcomes, the efficacy of FOLFOX is somewhat compromised by the emergence of drug resistance [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. In the present study, we generated HCC cell lines resistant to OXA and 5-Fu (the primary constituents of the FOLFOX regimen) and found that drug-resistant cells displayed enhanced glycolytic activity, which is consistent with previous investigations in this field [<xref ref-type="bibr" rid="CR54">54</xref>&#x02013;<xref ref-type="bibr" rid="CR56">56</xref>]. However, unlike previous studies, we discovered that active glycolysis impacts tumor cell drug resistance by regulating signaling pathways, and it also demonstrated that the glycolysis product lactate is a substrate that enhances HCC drug resistance through histone lactylation [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. Mechanistically, our studies showed that histone lactylation enhanced NEDD4 expression and that the interaction of NEDD4 with PTEN promoted PTEN ubiquitination and degradation, thereby promoting glycolysis in a positive feedback loop and ultimately leading to the development of resistance to OXA and 5-Fu.</p><p id="Par32">Although the mechanism of chemotherapy resistance in HCC has been extensively studied [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>], clinical practice often involves the use of multiple chemotherapeutic drugs in combination [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Therefore, it is necessary to study the resistance mechanism of the combined use of multiple chemotherapeutic drugs. Our study revealed that histone lactylation plays an important regulatory role in OXA-resistant HCC cells. Interestingly, 5-Fu has a similar mechanism of action in drug-resistant cell lines, suggesting that histone lactylation may play a significant role in multidrug resistance of HCC. The use of inhibitors that target histone lactylation effectively sensitized cells to HCC chemotherapy, which may provide a novel approach for the clinical treatment of chemoresistant patients.</p><p id="Par33">Metabolic reprogramming from oxidative phosphorylation to aerobic glycolysis, a phenomenon known as the &#x0201c;Warburg effect&#x0201d;, is a hallmark of cancer. Numerous studies have shown that glycolysis plays a regulatory role in tumor chemotherapy resistance by regulating intracellular redox, fat metabolism, and inducing cell death [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. However, we found in this study that glycolysis plays a regulatory role through the lactylation modification of protein lysine sites by its metabolite lactate. Zhang and colleagues discovered a chemical modification called lactylation, which originally referred to the addition of lactyl groups to lysine amino acid residues in histone tails, and altered gene expression levels [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. Furthermore, histone lactylation has been extensively studied in various fields, including tumors [<xref ref-type="bibr" rid="CR23">23</xref>], liver fibrosis [<xref ref-type="bibr" rid="CR66">66</xref>], and myocardial infarction [<xref ref-type="bibr" rid="CR67">67</xref>]. Since the discovery of histone lactylation, many genes regulated by it have been identified. In our study, we observed high levels of glycolysis and lactylation in OXA and 5-Fu resistant cells. In addition, we found that H3K14la played an important role in OXA and 5-Fu resistant HCC cells. Furthermore, based on ChIP-seq analysis, H3K14la was found to bind to the NEDD4 promoter region. Using a histone lactylation inhibitor and a silencing transferase (si-EP300), we subsequently demonstrated that NEDD4 is regulated by histone lactylation. To the best of our knowledge, this study is the first to report that NEDD4 is regulated by histone lactylation.</p><p id="Par34">As an E3 ligase, NEDD4 is highly expressed in breast cancer [<xref ref-type="bibr" rid="CR68">68</xref>], pancreatic cancer [<xref ref-type="bibr" rid="CR30">30</xref>], and gastric cancer [<xref ref-type="bibr" rid="CR69">69</xref>]. It is associated with poor survival in cancer patients by regulating tumor cell proliferation, apoptosis and stemness [<xref ref-type="bibr" rid="CR13">13</xref>]. NEDD4 has also been demonstrated to be involved in the resistance of tumor cells, including gastric cancer, glioblastoma and skin cancer cells, to chemotherapy [<xref ref-type="bibr" rid="CR70">70</xref>]. In this study, we also found that NEDD4 plays a cancer-promoting role in OXA-resistant cells by silencing NEDD4 (si-NEDD4), which is consistent with the findings of previous studies. Our study found that NEDD4 mediated the ubiquitination and degradation of PTEN by binding to PTEN, which activated the downstream PI3K/Akt/mTOR signaling pathway, thus promoting OXA and 5-Fu resistance in tumor cells. Previous studies have confirmed that NEDD4 is involved in the ubiquitination and degradation of the large tumor suppressor kinase 1 (LATS1) in tumor cells, thereby affecting the activity of the Hippo pathway [<xref ref-type="bibr" rid="CR13">13</xref>]. Additionally, NEDD4 plays a role in regulating the protein expression of guanylyl cyclase domain-containing 1 (GUCD1), insulin receptor substrate 2 (IRS-2), and other related proteins, contributing to its biological regulatory mechanisms [<xref ref-type="bibr" rid="CR71">71</xref>]. However, whether these mechanisms are also active in OXA- and 5-Fu-resistant HCC remains unexplained in this study. Interestingly, our study also found that the overexpression of PTEN in drug-resistant cells effectively reduced the levels of intracellular glycolysis, PKla, H3K14la, and NEDD4 levels, suggesting that glycolysis/H3K14la/PTEN positive feedback loop may exist in OXA- and 5-Fu- resistant cells. Restoring PTEN levels in drug-resistant cells may prove to be an effective therapeutic strategy. Although previous studies have shown that PTEN may affect glycolysis by regulating PKM2 and PFKFB3 [<xref ref-type="bibr" rid="CR72">72</xref>], this study did not investigate the specific molecular mechanism by which PTEN affects glycolysis. In conclusion, our study found that NEDD4 mediated PTEN ubiquitination in OXA and 5-Fu resistant HCC cells, thereby promoting active intracellular glycolysis to form a positive feedback loop. In addition, the degradation of PTEN also activated the PI3K/Akt/mTOR pathway, thus promoting the malignant behavior of cells. These findings elucidate potential targets for HCC drug resistance and provide an alternative mechanism for regulating PTEN that differs from previous studies.</p><p id="Par35">This study has certain limitations. First, there is a lack of support from clinical samples and supplementation in clinical trials. We studied OXA and 5-Fu resistant cell lines, but we were unable to construct FOLFOX-resistant HCC cell lines. In addition, we did not use commercially available multi-validated resistant strains due to the limitations of our conditions. Biological effects of the metabolic function of lactate cannot be completely ruled out, so whether lactylation and the metabolic effects of lactate coexist needs further study. In addition, whether there are other mechanisms of action in OXA- and 5-Fu-resistant cells, whether other targets of NEDD4 play a role, and the causal relationship between NEDD4 and lactylation modification in resistant cells remain to be further studied. Finally, further investigation is needed to elucidate the mechanism by which H3K14la regulates NEDD4 and its binding site on the promoter.</p><p id="Par36">Overall, our results demonstrate that histone lactylation leads to the upregulation of NEDD4 expression and facilitates PTEN ubiquitination and degradation. This process subsequently activates the PI3K/Akt/mTOR signaling pathway, promoting multidrug resistance in HCC. Fully clarifying the molecular mechanisms of HCC resistance to combined chemotherapy and chemotherapy resensitization represents a new therapeutic strategy for treating HCC.</p></sec><sec id="Sec23" sec-type="conclusion"><title>Conclusions</title><p id="Par37">Our study revealed that the level of intracellular lactylation, which plays a regulatory role in the form of histone lactylation, was increased in OXA- and 5-Fu-resistant HCC cells. H3K14la regulated NEDD4 expression and further promoted the ubiquitination and degradation of PTEN. Reduced PTEN activated the PI3K/Akt/mTOR signalling pathway and induced chemotherapy resistance in HCC. Furthermore, PTEN degradation alleviated the inhibition of intracellular glycolysis, thereby increasing the activity of intracellular glycolysis and establishing a positive feedback loop. Inhibiting intracellular histone lactylation could effectively inhibits the malignant progression of OXA and 5-Fu resistant cells and increases the sensitivity of HCC cells to chemotherapy (Fig. <xref rid="Fig9" ref-type="fig">9</xref>).<fig id="Fig9"><label>Fig. 9</label><caption><p>Illustration of the molecular mechanisms in OXA- and 5-Fu-resistant HCC.</p></caption><graphic xlink:href="41419_2025_7359_Fig9_HTML" id="d33e1388"/></fig></p></sec><sec id="Sec24" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41419_2025_7359_MOESM1_ESM.docx"><caption><p>Supplementary Figure</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41419_2025_7359_MOESM2_ESM.docx"><caption><p>Supplementary Methods</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41419_2025_7359_MOESM3_ESM.docx"><caption><p>Supplementary Table</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="41419_2025_7359_MOESM4_ESM.pdf"><caption><p>un-cropped images</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p>Edited by Francesca Bernassola</p></fn><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>These authors contributed equally: Yuan Zeng, Haoran Jiang.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41419-025-07359-9.</p></sec><ack><title>Acknowledgements</title><p>The ChIP-sequencing was performed by Lianchuan Bio (Hangzhou, China).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>YZ and HRJ designed and performed the experiments, analyzed the data, and wrote the manuscript; ZFC, HLY, YHL, HYY, RRZ, and XJZ performed cell experiments and animal studies and provided assistance; XJZ, RL, XTZ, JX, HYY, WMC, and PPM analyzed the data and prepared figures; HLY, JX, XTZ, XW, and YHL participated in the revision of the manuscript and checked the final manuscript; FJY and XW supervised the entire study, and FJY provided funding.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The project was supported by the Zhejiang Provincial Natural Science Foundation of China (No. LY23H030003), the Zhejiang Provincial Medical and Health Science and Technology Plan Project (No. 2024KY1264), the Wenzhou Municipal Science and Technology Bureau (No. Y20220024), and the National Science Foundation of China | Young Scientists Fund (No.82300668).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request. The full-length uncropped original Western blots were uploaded as &#x0201c;original Western blots&#x0201d;.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par38">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Ethics</title><p id="Par39">All animal experiments were approved by the Laboratory Animal Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University (WYYY-AEC-2022-029).</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Rumgay</surname><given-names>H</given-names></name><name><surname>Arnold</surname><given-names>M</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Lesi</surname><given-names>O</given-names></name><name><surname>Cabasag</surname><given-names>CJ</given-names></name><name><surname>Vignat</surname><given-names>J</given-names></name><etal/></person-group><article-title>Global burden of primary liver cancer in 2020 and predictions to 2040</article-title><source>J Hepatol</source><year>2022</year><volume>77</volume><fpage>1598</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2022.08.021</pub-id><pub-id pub-id-type="pmid">36208844</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598&#x02013;606.<pub-id pub-id-type="pmid">36208844</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><etal/></person-group><article-title>Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title><source>CA Cancer J Clin</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209&#x02013;49.<pub-id pub-id-type="pmid">33538338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Lyu</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>JB</given-names></name><name><surname>Lai</surname><given-names>JF</given-names></name><name><surname>Chen</surname><given-names>QF</given-names></name><name><surname>Li</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1)</article-title><source>J Clin Oncol</source><year>2022</year><volume>40</volume><fpage>468</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1200/JCO.21.01963</pub-id><pub-id pub-id-type="pmid">34905388</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li SL, et al. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). J Clin Oncol. 2022;40:468&#x02013;80.<pub-id pub-id-type="pmid">34905388</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>DY</given-names></name><name><surname>Zhu</surname><given-names>K</given-names></name><name><surname>Ren</surname><given-names>ZG</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name></person-group><article-title>A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights</article-title><source>Hepatobiliary Surg Nutr</source><year>2023</year><volume>12</volume><fpage>216</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.21037/hbsn-22-469</pub-id><pub-id pub-id-type="pmid">37124695</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Xie DY, Zhu K, Ren ZG, Zhou J, Fan J, Gao Q. A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2023;12:216&#x02013;28.<pub-id pub-id-type="pmid">37124695</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>A</given-names></name><name><surname>Kang</surname><given-names>L</given-names></name><name><surname>Cong</surname><given-names>R</given-names></name><name><surname>Fan</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><etal/></person-group><article-title>LSD1-Demethylated LINC01134 Confers Oxaliplatin Resistance Through SP1-Induced p62 Transcription in HCC</article-title><source>Hepatology</source><year>2021</year><volume>74</volume><fpage>3213</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1002/hep.32079</pub-id><pub-id pub-id-type="pmid">34322883</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Ma L, Xu A, Kang L, Cong R, Fan Z, Zhu X, et al. LSD1-Demethylated LINC01134 Confers Oxaliplatin Resistance Through SP1-Induced p62 Transcription in HCC. Hepatology. 2021;74:3213&#x02013;34.<pub-id pub-id-type="pmid">34322883</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Sidaway</surname><given-names>P</given-names></name></person-group><article-title>HAIC-FO improves outcomes in HCC</article-title><source>Nat Rev Clin Oncol</source><year>2022</year><volume>19</volume><fpage>150</fpage><pub-id pub-id-type="doi">10.1038/s41571-022-00599-0</pub-id><pub-id pub-id-type="pmid">35013583</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Sidaway P. HAIC-FO improves outcomes in HCC. Nat Rev Clin Oncol. 2022;19:150.<pub-id pub-id-type="pmid">35013583</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>Q</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma</article-title><source>J Exp Clin Cancer Res</source><year>2020</year><volume>39</volume><fpage>126</fpage><pub-id pub-id-type="doi">10.1186/s13046-020-01629-4</pub-id><pub-id pub-id-type="pmid">32631382</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Feng J, Li J, Wu L, Yu Q, Ji J, Wu J, et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020;39:126.<pub-id pub-id-type="pmid">32631382</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Ji</surname><given-names>N</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><etal/></person-group><article-title>Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression</article-title><source>Drug Resist Updat</source><year>2023</year><volume>69</volume><fpage>100976</fpage><pub-id pub-id-type="doi">10.1016/j.drup.2023.100976</pub-id><pub-id pub-id-type="pmid">37210811</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Wang S, Zhou L, Ji N, Sun C, Sun L, Sun J, et al. Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression. Drug Resist Updat. 2023;69:100976.<pub-id pub-id-type="pmid">37210811</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Cui</surname><given-names>C</given-names></name><name><surname>Weng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Metabolic regulation of gene expression by histone lactylation</article-title><source>Nature</source><year>2019</year><volume>574</volume><fpage>575</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1678-1</pub-id><pub-id pub-id-type="pmid">31645732</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Zhang D, Tang Z, Huang H, Zhou G, Cui C, Weng Y, et al. Metabolic regulation of gene expression by histone lactylation. Nature. 2019;574:575&#x02013;80.<pub-id pub-id-type="pmid">31645732</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Chai</surname><given-names>P</given-names></name><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Ge</surname><given-names>S</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><etal/></person-group><article-title>Histone lactylation drives oncogenesis by facilitating m(6)A reader protein YTHDF2 expression in ocular melanoma</article-title><source>Genome Biol</source><year>2021</year><volume>22</volume><fpage>85</fpage><pub-id pub-id-type="doi">10.1186/s13059-021-02308-z</pub-id><pub-id pub-id-type="pmid">33726814</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Yu J, Chai P, Xie M, Ge S, Ruan J, Fan X, et al. Histone lactylation drives oncogenesis by facilitating m(6)A reader protein YTHDF2 expression in ocular melanoma. Genome Biol. 2021;22:85.<pub-id pub-id-type="pmid">33726814</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-&#x003b2; signaling in regulatory T cells</article-title><source>Cell Rep</source><year>2022</year><volume>39</volume><fpage>110986</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2022.110986</pub-id><pub-id pub-id-type="pmid">35732125</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Gu J, Zhou J, Chen Q, Xu X, Gao J, Li X, et al. Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-&#x003b2; signaling in regulatory T cells. Cell Rep. 2022;39:110986.<pub-id pub-id-type="pmid">35732125</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Cen</surname><given-names>K</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Liou</surname><given-names>YC</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><etal/></person-group><article-title>NUSAP1-LDHA-Glycolysis-Lactate feedforward loop promotes Warburg effect and metastasis in pancreatic ductal adenocarcinoma</article-title><source>Cancer Lett</source><year>2023</year><volume>567</volume><fpage>216285</fpage><pub-id pub-id-type="doi">10.1016/j.canlet.2023.216285</pub-id><pub-id pub-id-type="pmid">37354982</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Chen M, Cen K, Song Y, Zhang X, Liou YC, Liu P, et al. NUSAP1-LDHA-Glycolysis-Lactate feedforward loop promotes Warburg effect and metastasis in pancreatic ductal adenocarcinoma. Cancer Lett. 2023;567:216285.<pub-id pub-id-type="pmid">37354982</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>ZW</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Chu</surname><given-names>M</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name></person-group><article-title>NEDD4 E3 ligase: Functions and mechanism in human cancer</article-title><source>Semin Cancer Biol</source><year>2020</year><volume>67</volume><fpage>92</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2020.03.006</pub-id><pub-id pub-id-type="pmid">32171886</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Wang ZW, Hu X, Ye M, Lin M, Chu M, Shen X. NEDD4 E3 ligase: Functions and mechanism in human cancer. Semin Cancer Biol. 2020;67:92&#x02013;101.<pub-id pub-id-type="pmid">32171886</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>T</given-names></name><name><surname>Connell</surname><given-names>DO</given-names></name><etal/></person-group><article-title>Nedd4 ubiquitylates VDAC2/3 to suppress erastin-induced ferroptosis in melanoma</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><fpage>433</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-14324-x</pub-id><pub-id pub-id-type="pmid">31974380</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Yang Y, Luo M, Zhang K, Zhang J, Gao T, Connell DO, et al. Nedd4 ubiquitylates VDAC2/3 to suppress erastin-induced ferroptosis in melanoma. Nat Commun. 2020;11:433.<pub-id pub-id-type="pmid">31974380</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Novellasdemunt</surname><given-names>L</given-names></name><name><surname>Kucharska</surname><given-names>A</given-names></name><name><surname>Jamieson</surname><given-names>C</given-names></name><name><surname>Prange-Barczynska</surname><given-names>M</given-names></name><name><surname>Baulies</surname><given-names>A</given-names></name><name><surname>Antas</surname><given-names>P</given-names></name><etal/></person-group><article-title>NEDD4 and NEDD4L regulate Wnt signalling and intestinal stem cell priming by degrading LGR5 receptor</article-title><source>EMBO J</source><year>2020</year><volume>39</volume><fpage>e102771</fpage><pub-id pub-id-type="doi">10.15252/embj.2019102771</pub-id><pub-id pub-id-type="pmid">31867777</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Novellasdemunt L, Kucharska A, Jamieson C, Prange-Barczynska M, Baulies A, Antas P, et al. NEDD4 and NEDD4L regulate Wnt signalling and intestinal stem cell priming by degrading LGR5 receptor. EMBO J. 2020;39:e102771.<pub-id pub-id-type="pmid">31867777</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>XY</given-names></name><name><surname>Liu</surname><given-names>TT</given-names></name><name><surname>Zhu</surname><given-names>WJ</given-names></name><name><surname>Liu</surname><given-names>HT</given-names></name><name><surname>Zhang</surname><given-names>GH</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><etal/></person-group><article-title>CircKDM4B suppresses breast cancer progression via the miR-675/NEDD4L axis</article-title><source>Oncogene</source><year>2022</year><volume>41</volume><fpage>1895</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1038/s41388-022-02232-x</pub-id><pub-id pub-id-type="pmid">35145234</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Guo XY, Liu TT, Zhu WJ, Liu HT, Zhang GH, Song L, et al. CircKDM4B suppresses breast cancer progression via the miR-675/NEDD4L axis. Oncogene. 2022;41:1895&#x02013;906.<pub-id pub-id-type="pmid">35145234</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Ning</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Teng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Brain endothelial PTEN/AKT/NEDD4-2/MFSD2A axis regulates blood-brain barrier permeability</article-title><source>Cell Rep</source><year>2021</year><volume>36</volume><fpage>109327</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109327</pub-id><pub-id pub-id-type="pmid">34233198</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Cui Y, Wang Y, Song X, Ning H, Zhang Y, Teng Y, et al. Brain endothelial PTEN/AKT/NEDD4-2/MFSD2A axis regulates blood-brain barrier permeability. Cell Rep. 2021;36:109327.<pub-id pub-id-type="pmid">34233198</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Bu</surname><given-names>Y</given-names></name><name><surname>Jia</surname><given-names>QA</given-names></name><name><surname>Ren</surname><given-names>ZG</given-names></name><name><surname>Zhang</surname><given-names>JB</given-names></name><name><surname>Jiang</surname><given-names>XM</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma is associated with increased autocrine of IGF1</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e89686</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0089686</pub-id><pub-id pub-id-type="pmid">24632571</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Bu Y, Jia QA, Ren ZG, Zhang JB, Jiang XM, Liang L, et al. Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma is associated with increased autocrine of IGF1. PLoS One. 2014;9:e89686.<pub-id pub-id-type="pmid">24632571</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>JH</given-names></name><name><surname>Chen</surname><given-names>PH</given-names></name><name><surname>Liu</surname><given-names>HD</given-names></name><name><surname>Huang</surname><given-names>DA</given-names></name><name><surname>Li</surname><given-names>MM</given-names></name><name><surname>Guo</surname><given-names>K</given-names></name></person-group><article-title>HSF1/AMPK&#x003b1;2 mediated alteration of metabolic phenotypes confers increased oxaliplatin resistance in HCC cells</article-title><source>Am J Cancer Res</source><year>2019</year><volume>9</volume><fpage>2349</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">31815039</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Shen JH, Chen PH, Liu HD, Huang DA, Li MM, Guo K. HSF1/AMPK&#x003b1;2 mediated alteration of metabolic phenotypes confers increased oxaliplatin resistance in HCC cells. Am J Cancer Res. 2019;9:2349&#x02013;63.<pub-id pub-id-type="pmid">31815039</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Pu</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>D</given-names></name><name><surname>Tu</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><etal/></person-group><article-title>CDK Inhibition Reverses Acquired 5-Fluorouracil Resistance in Hepatocellular Carcinoma Cells</article-title><source>Dis Markers</source><year>2022</year><volume>2022</volume><fpage>6907057</fpage><pub-id pub-id-type="doi">10.1155/2022/6907057</pub-id><pub-id pub-id-type="pmid">35308136</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Pu Y, Yan D, Tu L, Cheng L, Yu J, Li Z, et al. CDK Inhibition Reverses Acquired 5-Fluorouracil Resistance in Hepatocellular Carcinoma Cells. Dis Markers. 2022;2022:6907057.<pub-id pub-id-type="pmid">35308136</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Uchibori</surname><given-names>K</given-names></name><name><surname>Kasamatsu</surname><given-names>A</given-names></name><name><surname>Sunaga</surname><given-names>M</given-names></name><name><surname>Yokota</surname><given-names>S</given-names></name><name><surname>Sakurada</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines</article-title><source>Int J Oncol</source><year>2012</year><volume>40</volume><fpage>1005</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.3892/ijo.2011.1300</pub-id><pub-id pub-id-type="pmid">22179686</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Uchibori K, Kasamatsu A, Sunaga M, Yokota S, Sakurada T, Kobayashi E, et al. Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines. Int J Oncol. 2012;40:1005&#x02013;10.<pub-id pub-id-type="pmid">22179686</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>KW</given-names></name><name><surname>Kamocka</surname><given-names>MM</given-names></name><name><surname>McDonald</surname><given-names>JH</given-names></name></person-group><article-title>A practical guide to evaluating colocalization in biological microscopy</article-title><source>Am J Physiol Cell Physiol</source><year>2011</year><volume>300</volume><fpage>C723</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00462.2010</pub-id><pub-id pub-id-type="pmid">21209361</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Dunn KW, Kamocka MM, McDonald JH. A practical guide to evaluating colocalization in biological microscopy. Am J Physiol Cell Physiol. 2011;300:C723&#x02013;42.<pub-id pub-id-type="pmid">21209361</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Li W, Zhou C, Yu L, Hou Z, Liu H, Kong L, et al. Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer. Autophagy. 2024;20:114&#x02013;30.</mixed-citation></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Vahabi</surname><given-names>M</given-names></name><name><surname>Comandatore</surname><given-names>A</given-names></name><name><surname>Franczak</surname><given-names>MA</given-names></name><name><surname>Smolenski</surname><given-names>RT</given-names></name><name><surname>Peters</surname><given-names>GJ</given-names></name><name><surname>Morelli</surname><given-names>L</given-names></name><etal/></person-group><article-title>Role of exosomes in transferring chemoresistance through modulation of cancer glycolytic cell metabolism</article-title><source>Cytokine Growth Factor Rev</source><year>2023</year><volume>73</volume><fpage>163</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2023.07.004</pub-id><pub-id pub-id-type="pmid">37541790</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Vahabi M, Comandatore A, Franczak MA, Smolenski RT, Peters GJ, Morelli L, et al. Role of exosomes in transferring chemoresistance through modulation of cancer glycolytic cell metabolism. Cytokine Growth Factor Rev. 2023;73:163&#x02013;72.<pub-id pub-id-type="pmid">37541790</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>JQ</given-names></name><name><surname>Assaraf</surname><given-names>YG</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Gupta</surname><given-names>P</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><etal/></person-group><article-title>Modulating ROS to overcome multidrug resistance in cancer</article-title><source>Drug Resist Updat</source><year>2018</year><volume>41</volume><fpage>1</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.drup.2018.11.001</pub-id><pub-id pub-id-type="pmid">30471641</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Cui Q, Wang JQ, Assaraf YG, Ren L, Gupta P, Wei L, et al. Modulating ROS to overcome multidrug resistance in cancer. Drug Resist Updat. 2018;41:1&#x02013;25.<pub-id pub-id-type="pmid">30471641</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez Krol</surname><given-names>A</given-names></name><name><surname>Nehring</surname><given-names>HP</given-names></name><name><surname>Krause</surname><given-names>FF</given-names></name><name><surname>Wempe</surname><given-names>A</given-names></name><name><surname>Raifer</surname><given-names>H</given-names></name><name><surname>Nist</surname><given-names>A</given-names></name><etal/></person-group><article-title>Lactate induces metabolic and epigenetic reprogramming of pro-inflammatory Th17 cells</article-title><source>EMBO Rep</source><year>2022</year><volume>23</volume><fpage>e54685</fpage><pub-id pub-id-type="doi">10.15252/embr.202254685</pub-id><pub-id pub-id-type="pmid">36215678</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Lopez Krol A, Nehring HP, Krause FF, Wempe A, Raifer H, Nist A, et al. Lactate induces metabolic and epigenetic reprogramming of pro-inflammatory Th17 cells. EMBO Rep. 2022;23:e54685.<pub-id pub-id-type="pmid">36215678</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>Ding</surname><given-names>RC</given-names></name><name><surname>Yu</surname><given-names>Q</given-names></name><name><surname>Qiu</surname><given-names>CZ</given-names></name><name><surname>Zhang</surname><given-names>HY</given-names></name><name><surname>Yin</surname><given-names>ZJ</given-names></name><etal/></person-group><article-title>Metformin Attenuates Neutrophil Recruitment through the H3K18 Lactylation/Reactive Oxygen Species Pathway in Zebrafish</article-title><source>Antioxidants</source><year>2024</year><volume>13</volume><fpage>176</fpage><pub-id pub-id-type="doi">10.3390/antiox13020176</pub-id><pub-id pub-id-type="pmid">38397774</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Zhou R, Ding RC, Yu Q, Qiu CZ, Zhang HY, Yin ZJ, et al. Metformin Attenuates Neutrophil Recruitment through the H3K18 Lactylation/Reactive Oxygen Species Pathway in Zebrafish. Antioxidants. 2024;13:176.<pub-id pub-id-type="pmid">38397774</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>B</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Lv</surname><given-names>T</given-names></name><name><surname>Ye</surname><given-names>J</given-names></name><etal/></person-group><article-title>The walnut-derived peptide TW-7 improves mouse parthenogenetic embryo development of vitrified MII oocytes potentially by promoting histone lactylation</article-title><source>J Anim Sci Biotechnol</source><year>2024</year><volume>15</volume><fpage>86</fpage><pub-id pub-id-type="doi">10.1186/s40104-024-01045-0</pub-id><pub-id pub-id-type="pmid">38858724</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Wei Y, Pan B, Qin J, Cao B, Lv T, Ye J, et al. The walnut-derived peptide TW-7 improves mouse parthenogenetic embryo development of vitrified MII oocytes potentially by promoting histone lactylation. J Anim Sci Biotechnol. 2024;15:86.<pub-id pub-id-type="pmid">38858724</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name></person-group><article-title>Nedd4 and Nedd4-2: closely related ubiquitin-protein ligases with distinct physiological functions</article-title><source>Cell Death Differ</source><year>2010</year><volume>17</volume><fpage>68</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1038/cdd.2009.84</pub-id><pub-id pub-id-type="pmid">19557014</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Yang B, Kumar S. Nedd4 and Nedd4-2: closely related ubiquitin-protein ligases with distinct physiological functions. Cell Death Differ. 2010;17:68&#x02013;77.<pub-id pub-id-type="pmid">19557014</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>N4BP3 promotes breast cancer metastasis via NEDD4-mediated E-cadherin ubiquitination and degradation</article-title><source>Cancer Lett</source><year>2022</year><volume>550</volume><fpage>215926</fpage><pub-id pub-id-type="doi">10.1016/j.canlet.2022.215926</pub-id><pub-id pub-id-type="pmid">36162713</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Luo M, Li J, Yang Q, Xu S, Zhang K, Chen J, et al. N4BP3 promotes breast cancer metastasis via NEDD4-mediated E-cadherin ubiquitination and degradation. Cancer Lett. 2022;550:215926.<pub-id pub-id-type="pmid">36162713</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Jing</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Cui</surname><given-names>Z</given-names></name><name><surname>Xiong</surname><given-names>G</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance</article-title><source>Cancer Res</source><year>2022</year><volume>82</volume><fpage>114</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-21-2362</pub-id><pub-id pub-id-type="pmid">34753771</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Jing W, Wang G, Cui Z, Xiong G, Jiang X, Li Y, et al. FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance. Cancer Res. 2022;82:114&#x02013;29.<pub-id pub-id-type="pmid">34753771</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Lian</surname><given-names>C</given-names></name><name><surname>Cao</surname><given-names>T</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><etal/></person-group><article-title>Nitidine chloride suppresses NEDD4 expression in lung cancer cells</article-title><source>Aging</source><year>2020</year><volume>13</volume><fpage>782</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.18632/aging.202185</pub-id><pub-id pub-id-type="pmid">33288736</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Zhang J, Cao R, Lian C, Cao T, Shi Y, Ma J, et al. Nitidine chloride suppresses NEDD4 expression in lung cancer cells. Aging. 2020;13:782&#x02013;93.<pub-id pub-id-type="pmid">33288736</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Amraei</surname><given-names>R</given-names></name><name><surname>Rahimi</surname><given-names>N</given-names></name></person-group><article-title>NEDD4 regulates ubiquitination and stability of the cell adhesion molecule IGPR-1 via lysosomal pathway</article-title><source>J Biomed Sci</source><year>2021</year><volume>28</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.1186/s12929-021-00731-9</pub-id><pub-id pub-id-type="pmid">33962630</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Sun L, Amraei R, Rahimi N. NEDD4 regulates ubiquitination and stability of the cell adhesion molecule IGPR-1 via lysosomal pathway. J Biomed Sci. 2021;28:35.<pub-id pub-id-type="pmid">33962630</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Drinjakovic</surname><given-names>J</given-names></name><name><surname>Jung</surname><given-names>H</given-names></name><name><surname>Campbell</surname><given-names>DS</given-names></name><name><surname>Strochlic</surname><given-names>L</given-names></name><name><surname>Dwivedy</surname><given-names>A</given-names></name><name><surname>Holt</surname><given-names>CE</given-names></name></person-group><article-title>E3 ligase Nedd4 promotes axon branching by downregulating PTEN</article-title><source>Neuron</source><year>2010</year><volume>65</volume><fpage>341</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2010.01.017</pub-id><pub-id pub-id-type="pmid">20159448</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Drinjakovic J, Jung H, Campbell DS, Strochlic L, Dwivedy A, Holt CE. E3 ligase Nedd4 promotes axon branching by downregulating PTEN. Neuron. 2010;65:341&#x02013;57.<pub-id pub-id-type="pmid">20159448</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Fouladkou</surname><given-names>F</given-names></name><name><surname>Landry</surname><given-names>T</given-names></name><name><surname>Kawabe</surname><given-names>H</given-names></name><name><surname>Neeb</surname><given-names>A</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Brose</surname><given-names>N</given-names></name><etal/></person-group><article-title>The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization</article-title><source>Proc Natl Acad Sci USA</source><year>2008</year><volume>105</volume><fpage>8585</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1073/pnas.0803233105</pub-id><pub-id pub-id-type="pmid">18562292</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Fouladkou F, Landry T, Kawabe H, Neeb A, Lu C, Brose N, et al. The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization. Proc Natl Acad Sci USA. 2008;105:8585&#x02013;90.<pub-id pub-id-type="pmid">18562292</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Trotman</surname><given-names>LC</given-names></name><name><surname>Koppie</surname><given-names>T</given-names></name><name><surname>Alimonti</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><etal/></person-group><article-title>NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN</article-title><source>Cell</source><year>2007</year><volume>128</volume><fpage>129</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.11.039</pub-id><pub-id pub-id-type="pmid">17218260</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell. 2007;128:129&#x02013;39.<pub-id pub-id-type="pmid">17218260</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Maccario</surname><given-names>H</given-names></name><name><surname>Perera</surname><given-names>NM</given-names></name><name><surname>Gray</surname><given-names>A</given-names></name><name><surname>Downes</surname><given-names>CP</given-names></name><name><surname>Leslie</surname><given-names>NR</given-names></name></person-group><article-title>Ubiquitination of PTEN (phosphatase and tensin homolog) inhibits phosphatase activity and is enhanced by membrane targeting and hyperosmotic stress</article-title><source>J Biol Chem</source><year>2010</year><volume>285</volume><fpage>12620</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.072280</pub-id><pub-id pub-id-type="pmid">20177066</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Maccario H, Perera NM, Gray A, Downes CP, Leslie NR. Ubiquitination of PTEN (phosphatase and tensin homolog) inhibits phosphatase activity and is enhanced by membrane targeting and hyperosmotic stress. J Biol Chem. 2010;285:12620&#x02013;8.<pub-id pub-id-type="pmid">20177066</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Mao</surname><given-names>C</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The deubiquitinase USP10 restores PTEN activity and inhibits non-small cell lung cancer cell proliferation</article-title><source>J Biol Chem</source><year>2021</year><volume>297</volume><fpage>101088</fpage><pub-id pub-id-type="doi">10.1016/j.jbc.2021.101088</pub-id><pub-id pub-id-type="pmid">34416231</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">He Y, Jiang S, Mao C, Zheng H, Cao B, Zhang Z, et al. The deubiquitinase USP10 restores PTEN activity and inhibits non-small cell lung cancer cell proliferation. J Biol Chem. 2021;297:101088.<pub-id pub-id-type="pmid">34416231</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Vidotto</surname><given-names>T</given-names></name><name><surname>Melo</surname><given-names>CM</given-names></name><name><surname>Castelli</surname><given-names>E</given-names></name><name><surname>Koti</surname><given-names>M</given-names></name><name><surname>Dos Reis</surname><given-names>RB</given-names></name><name><surname>Squire</surname><given-names>JA</given-names></name></person-group><article-title>Emerging role of PTEN loss in evasion of the immune response to tumours</article-title><source>Br J Cancer</source><year>2020</year><volume>122</volume><fpage>1732</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1038/s41416-020-0834-6</pub-id><pub-id pub-id-type="pmid">32327707</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Vidotto T, Melo CM, Castelli E, Koti M, Dos Reis RB, Squire JA. Emerging role of PTEN loss in evasion of the immune response to tumours. Br J Cancer. 2020;122:1732&#x02013;43.<pub-id pub-id-type="pmid">32327707</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name></person-group><article-title>Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis</article-title><source>Proc Natl Acad Sci USA</source><year>2020</year><volume>117</volume><fpage>31189</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1073/pnas.2017152117</pub-id><pub-id pub-id-type="pmid">33229547</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Yi J, Zhu J, Wu J, Thompson CB, Jiang X. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. Proc Natl Acad Sci USA. 2020;117:31189&#x02013;97.<pub-id pub-id-type="pmid">33229547</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Hashemi</surname><given-names>M</given-names></name><name><surname>Etemad</surname><given-names>S</given-names></name><name><surname>Rezaei</surname><given-names>S</given-names></name><name><surname>Ziaolhagh</surname><given-names>S</given-names></name><name><surname>Rajabi</surname><given-names>R</given-names></name><name><surname>Rahmanian</surname><given-names>P</given-names></name><etal/></person-group><article-title>Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy: Revisiting molecular interactions</article-title><source>Biomed Pharmacother</source><year>2023</year><volume>158</volume><fpage>114204</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2022.114204</pub-id><pub-id pub-id-type="pmid">36916430</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Hashemi M, Etemad S, Rezaei S, Ziaolhagh S, Rajabi R, Rahmanian P, et al. Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy: Revisiting molecular interactions. Biomed Pharmacother. 2023;158:114204.<pub-id pub-id-type="pmid">36916430</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>T</given-names></name><name><surname>Long</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name></person-group><article-title>NEDD4 and NEDD4L: Ubiquitin Ligases Closely Related to Digestive Diseases</article-title><source>Biomolecules</source><year>2024</year><volume>14</volume><fpage>577</fpage><pub-id pub-id-type="doi">10.3390/biom14050577</pub-id><pub-id pub-id-type="pmid">38785984</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Xu J, Jiang W, Hu T, Long Y, Shen Y. NEDD4 and NEDD4L: Ubiquitin Ligases Closely Related to Digestive Diseases. Biomolecules. 2024;14:577.<pub-id pub-id-type="pmid">38785984</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Kovacevic</surname><given-names>Z</given-names></name><name><surname>Chikhani</surname><given-names>S</given-names></name><name><surname>Lui</surname><given-names>GY</given-names></name><name><surname>Sivagurunathan</surname><given-names>S</given-names></name><name><surname>Richardson</surname><given-names>DR</given-names></name></person-group><article-title>The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways</article-title><source>Antioxid Redox Signal</source><year>2013</year><volume>18</volume><fpage>874</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1089/ars.2011.4273</pub-id><pub-id pub-id-type="pmid">22462691</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Kovacevic Z, Chikhani S, Lui GY, Sivagurunathan S, Richardson DR. The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways. Antioxid Redox Signal. 2013;18:874&#x02013;87.<pub-id pub-id-type="pmid">22462691</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Mei</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Shi</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><etal/></person-group><article-title>Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma: a multi-center propensity score matched analysis of real-world practice</article-title><source>Hepatobiliary Surg Nutr</source><year>2021</year><volume>10</volume><fpage>631</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.21037/hbsn.2020.03.14</pub-id><pub-id pub-id-type="pmid">34760967</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Li S, Mei J, Wang Q, Shi F, Liu H, Zhao M, et al. Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma: a multi-center propensity score matched analysis of real-world practice. Hepatobiliary Surg Nutr. 2021;10:631&#x02013;45.<pub-id pub-id-type="pmid">34760967</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Lyu</surname><given-names>N</given-names></name><name><surname>Kong</surname><given-names>Y</given-names></name><name><surname>Mu</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma</article-title><source>J Hepatol</source><year>2018</year><volume>69</volume><fpage>60</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2018.02.008</pub-id><pub-id pub-id-type="pmid">29471013</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Lyu N, Kong Y, Mu L, Lin Y, Li J, Liu Y, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2018;69:60&#x02013;9.<pub-id pub-id-type="pmid">29471013</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Andreucci</surname><given-names>E</given-names></name><name><surname>Biagioni</surname><given-names>A</given-names></name><name><surname>Peri</surname><given-names>S</given-names></name><name><surname>Versienti</surname><given-names>G</given-names></name><name><surname>Cianchi</surname><given-names>F</given-names></name><name><surname>Staderini</surname><given-names>F</given-names></name><etal/></person-group><article-title>The CAIX inhibitor SLC-0111 exerts anti-cancer activity on gastric cancer cell lines and resensitizes resistant cells to 5-Fluorouracil, taxane-derived, and platinum-based drugs</article-title><source>Cancer Lett</source><year>2023</year><volume>571</volume><fpage>216338</fpage><pub-id pub-id-type="doi">10.1016/j.canlet.2023.216338</pub-id><pub-id pub-id-type="pmid">37549770</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Andreucci E, Biagioni A, Peri S, Versienti G, Cianchi F, Staderini F, et al. The CAIX inhibitor SLC-0111 exerts anti-cancer activity on gastric cancer cell lines and resensitizes resistant cells to 5-Fluorouracil, taxane-derived, and platinum-based drugs. Cancer Lett. 2023;571:216338.<pub-id pub-id-type="pmid">37549770</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Torregrosa</surname><given-names>C</given-names></name><name><surname>Pernot</surname><given-names>S</given-names></name><name><surname>Vaflard</surname><given-names>P</given-names></name><name><surname>Perret</surname><given-names>A</given-names></name><name><surname>Tournigand</surname><given-names>C</given-names></name><name><surname>Randrian</surname><given-names>V</given-names></name><etal/></person-group><article-title>FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study</article-title><source>Int J Cancer</source><year>2022</year><volume>151</volume><fpage>1978</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1002/ijc.34166</pub-id><pub-id pub-id-type="pmid">35833561</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Torregrosa C, Pernot S, Vaflard P, Perret A, Tournigand C, Randrian V, et al. FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study. Int J Cancer. 2022;151:1978&#x02013;88.<pub-id pub-id-type="pmid">35833561</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Ortega-Molina</surname><given-names>A</given-names></name><name><surname>Serrano</surname><given-names>M</given-names></name></person-group><article-title>PTEN in cancer, metabolism, and aging</article-title><source>Trends Endocrinol Metab</source><year>2013</year><volume>24</volume><fpage>184</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2012.11.002</pub-id><pub-id pub-id-type="pmid">23245767</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Ortega-Molina A, Serrano M. PTEN in cancer, metabolism, and aging. Trends Endocrinol Metab. 2013;24:184&#x02013;9.<pub-id pub-id-type="pmid">23245767</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Endicott</surname><given-names>SJ</given-names></name><name><surname>Miller</surname><given-names>RA</given-names></name></person-group><article-title>PTEN activates chaperone-mediated autophagy to regulate metabolism</article-title><source>Autophagy</source><year>2024</year><volume>20</volume><fpage>216</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1080/15548627.2023.2255966</pub-id><pub-id pub-id-type="pmid">37669771</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Endicott SJ, Miller RA. PTEN activates chaperone-mediated autophagy to regulate metabolism. Autophagy. 2024;20:216&#x02013;7.<pub-id pub-id-type="pmid">37669771</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Down-regulation of miR-214 inhibits proliferation and glycolysis in non-small-cell lung cancer cells via down-regulating the expression of hexokinase 2 and pyruvate kinase isozyme M2</article-title><source>Biomed Pharmacother</source><year>2018</year><volume>105</volume><fpage>545</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.06.009</pub-id><pub-id pub-id-type="pmid">29886375</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Zhang K, Zhang M, Jiang H, Liu F, Liu H, Li Y. Down-regulation of miR-214 inhibits proliferation and glycolysis in non-small-cell lung cancer cells via down-regulating the expression of hexokinase 2 and pyruvate kinase isozyme M2. Biomed Pharmacother. 2018;105:545&#x02013;52.<pub-id pub-id-type="pmid">29886375</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Yalcin</surname><given-names>A</given-names></name><name><surname>Clem</surname><given-names>BF</given-names></name><name><surname>Imbert-Fernandez</surname><given-names>Y</given-names></name><name><surname>Ozcan</surname><given-names>SC</given-names></name><name><surname>Peker</surname><given-names>S</given-names></name><name><surname>O&#x02019;Neal</surname><given-names>J</given-names></name><etal/></person-group><article-title>6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27</article-title><source>Cell Death Dis</source><year>2014</year><volume>5</volume><fpage>e1337</fpage><pub-id pub-id-type="doi">10.1038/cddis.2014.292</pub-id><pub-id pub-id-type="pmid">25032860</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Yalcin A, Clem BF, Imbert-Fernandez Y, Ozcan SC, Peker S, O&#x02019;Neal J, et al. 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27. Cell Death Dis. 2014;5:e1337.<pub-id pub-id-type="pmid">25032860</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name></person-group><article-title>Formulation of two lipid-based membrane-core nanoparticles for FOLFOX combination therapy</article-title><source>Nat Protoc</source><year>2022</year><volume>17</volume><fpage>1818</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1038/s41596-022-00698-3</pub-id><pub-id pub-id-type="pmid">35650451</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Guo J, Huang L. Formulation of two lipid-based membrane-core nanoparticles for FOLFOX combination therapy. Nat Protoc. 2022;17:1818&#x02013;31.<pub-id pub-id-type="pmid">35650451</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Taieb</surname><given-names>J</given-names></name><name><surname>Balogoun</surname><given-names>R</given-names></name><name><surname>Le Malicot</surname><given-names>K</given-names></name><name><surname>Tabernero</surname><given-names>J</given-names></name><name><surname>Mini</surname><given-names>E</given-names></name><name><surname>Folprecht</surname><given-names>G</given-names></name><etal/></person-group><article-title>Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients</article-title><source>Ann Oncol</source><year>2017</year><volume>28</volume><fpage>824</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdw687</pub-id><pub-id pub-id-type="pmid">28031175</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Taieb J, Balogoun R, Le Malicot K, Tabernero J, Mini E, Folprecht G, et al. Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients. Ann Oncol. 2017;28:824&#x02013;30.<pub-id pub-id-type="pmid">28031175</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Xia</surname><given-names>L</given-names></name><name><surname>Oyang</surname><given-names>L</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>N</given-names></name><etal/></person-group><article-title>The POU2F1-ALDOA axis promotes the proliferation and chemoresistance of colon cancer cells by enhancing glycolysis and the pentose phosphate pathway activity</article-title><source>Oncogene</source><year>2022</year><volume>41</volume><fpage>1024</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1038/s41388-021-02148-y</pub-id><pub-id pub-id-type="pmid">34997215</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Lin J, Xia L, Oyang L, Liang J, Tan S, Wu N, et al. The POU2F1-ALDOA axis promotes the proliferation and chemoresistance of colon cancer cells by enhancing glycolysis and the pentose phosphate pathway activity. Oncogene. 2022;41:1024&#x02013;39.<pub-id pub-id-type="pmid">34997215</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Tu</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>N(6)-methyladenosine-mediated LDHA induction potentiates chemoresistance of colorectal cancer cells through metabolic reprogramming</article-title><source>Theranostics</source><year>2022</year><volume>12</volume><fpage>4802</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.7150/thno.73746</pub-id><pub-id pub-id-type="pmid">35832094</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Zhang K, Zhang T, Yang Y, Tu W, Huang H, Wang Y, et al. N(6)-methyladenosine-mediated LDHA induction potentiates chemoresistance of colorectal cancer cells through metabolic reprogramming. Theranostics. 2022;12:4802&#x02013;17.<pub-id pub-id-type="pmid">35832094</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><etal/></person-group><article-title>ROS/PI3K/Akt and Wnt/&#x003b2;-catenin signalings activate HIF-1&#x003b1;-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer</article-title><source>J Exp Clin Cancer Res</source><year>2022</year><volume>41</volume><fpage>15</fpage><pub-id pub-id-type="doi">10.1186/s13046-021-02229-6</pub-id><pub-id pub-id-type="pmid">34998404</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Dong S, Liang S, Cheng Z, Zhang X, Luo L, Li L, et al. ROS/PI3K/Akt and Wnt/&#x003b2;-catenin signalings activate HIF-1&#x003b1;-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer. J Exp Clin Cancer Res. 2022;41:15.<pub-id pub-id-type="pmid">34998404</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Mu</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Circadian clock gene NPAS2 promotes reprogramming of glucose metabolism in hepatocellular carcinoma cells</article-title><source>Cancer Lett</source><year>2020</year><volume>469</volume><fpage>498</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2019.11.024</pub-id><pub-id pub-id-type="pmid">31765736</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Yuan P, Yang T, Mu J, Zhao J, Yang Y, Yan Z, et al. Circadian clock gene NPAS2 promotes reprogramming of glucose metabolism in hepatocellular carcinoma cells. Cancer Lett. 2020;469:498&#x02013;509.<pub-id pub-id-type="pmid">31765736</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolism</article-title><source>Redox Biol</source><year>2022</year><volume>56</volume><fpage>102458</fpage><pub-id pub-id-type="doi">10.1016/j.redox.2022.102458</pub-id><pub-id pub-id-type="pmid">36116159</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Zhou Q, Yin Y, Yu M, Gao D, Sun J, Yang Z, et al. GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolism. Redox Biol. 2022;56:102458.<pub-id pub-id-type="pmid">36116159</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Long</surname><given-names>J</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Liao</surname><given-names>J</given-names></name><etal/></person-group><article-title>METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma</article-title><source>Cancer Res</source><year>2023</year><volume>83</volume><fpage>89</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-22-0963</pub-id><pub-id pub-id-type="pmid">36102722</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Huang M, Long J, Yao Z, Zhao Y, Zhao Y, Liao J, et al. METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma. Cancer Res. 2023;83:89&#x02013;102.<pub-id pub-id-type="pmid">36102722</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Han</surname><given-names>Q</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><etal/></person-group><article-title>Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway</article-title><source>Cancer Lett</source><year>2019</year><volume>444</volume><fpage>82</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2018.12.010</pub-id><pub-id pub-id-type="pmid">30583078</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Wang J, Zhang N, Han Q, Lu W, Wang L, Yang D, et al. Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway. Cancer Lett. 2019;444:82&#x02013;93.<pub-id pub-id-type="pmid">30583078</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>AX</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name><name><surname>Qin</surname><given-names>W</given-names></name><etal/></person-group><article-title>Evolving therapeutic landscape of advanced hepatocellular carcinoma</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2023</year><volume>20</volume><fpage>203</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1038/s41575-022-00704-9</pub-id><pub-id pub-id-type="pmid">36369487</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2023;20:203&#x02013;22.<pub-id pub-id-type="pmid">36369487</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>De Baere</surname><given-names>T</given-names></name><name><surname>Kulik</surname><given-names>L</given-names></name><name><surname>Haber</surname><given-names>PK</given-names></name><name><surname>Greten</surname><given-names>TF</given-names></name><name><surname>Meyer</surname><given-names>T</given-names></name><etal/></person-group><article-title>Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2021</year><volume>18</volume><fpage>293</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1038/s41575-020-00395-0</pub-id><pub-id pub-id-type="pmid">33510460</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18:293&#x02013;313.<pub-id pub-id-type="pmid">33510460</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Yu</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name></person-group><article-title>Mitochondrial fragmentation in liver cancer: Emerging player and promising therapeutic opportunities</article-title><source>Cancer Lett</source><year>2022</year><volume>549</volume><fpage>215912</fpage><pub-id pub-id-type="doi">10.1016/j.canlet.2022.215912</pub-id><pub-id pub-id-type="pmid">36103914</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Wang Q, Yu P, Liu C, He X, Wang G. Mitochondrial fragmentation in liver cancer: Emerging player and promising therapeutic opportunities. Cancer Lett. 2022;549:215912.<pub-id pub-id-type="pmid">36103914</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Mang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>Z</given-names></name><name><surname>Tan</surname><given-names>F</given-names></name></person-group><article-title>Piezoeletric cold atmospheric plasma induces apoptosis and autophagy in human hepatocellular carcinoma cells through blocking glycolysis and AKT/mTOR/HIF-1&#x003b1; pathway</article-title><source>Free Radic Biol Med</source><year>2023</year><volume>208</volume><fpage>134</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2023.07.036</pub-id><pub-id pub-id-type="pmid">37543168</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Wang Y, Mang X, Li D, Chen Y, Cai Z, Tan F. Piezoeletric cold atmospheric plasma induces apoptosis and autophagy in human hepatocellular carcinoma cells through blocking glycolysis and AKT/mTOR/HIF-1&#x003b1; pathway. Free Radic Biol Med. 2023;208:134&#x02013;52.<pub-id pub-id-type="pmid">37543168</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Izzo</surname><given-names>LT</given-names></name><name><surname>Wellen</surname><given-names>KE</given-names></name></person-group><article-title>Histone lactylation links metabolism and gene regulation</article-title><source>Nature</source><year>2019</year><volume>574</volume><fpage>492</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1038/d41586-019-03122-1</pub-id><pub-id pub-id-type="pmid">31645737</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Izzo LT, Wellen KE. Histone lactylation links metabolism and gene regulation. Nature. 2019;574:492&#x02013;3.<pub-id pub-id-type="pmid">31645737</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Rho</surname><given-names>H</given-names></name><name><surname>Terry</surname><given-names>AR</given-names></name><name><surname>Chronis</surname><given-names>C</given-names></name><name><surname>Hay</surname><given-names>N</given-names></name></person-group><article-title>Hexokinase 2-mediated gene expression via histone lactylation is required for hepatic stellate cell activation and liver fibrosis</article-title><source>Cell Metab</source><year>2023</year><volume>35</volume><fpage>1406</fpage><lpage>23.e8</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2023.06.013</pub-id><pub-id pub-id-type="pmid">37463576</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Rho H, Terry AR, Chronis C, Hay N. Hexokinase 2-mediated gene expression via histone lactylation is required for hepatic stellate cell activation and liver fibrosis. Cell Metab. 2023;35:1406&#x02013;23.e8.<pub-id pub-id-type="pmid">37463576</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Mang</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>X</given-names></name><etal/></person-group><article-title>Histone Lactylation Boosts Reparative Gene Activation Post-Myocardial Infarction</article-title><source>Circ Res</source><year>2022</year><volume>131</volume><fpage>893</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.122.320488</pub-id><pub-id pub-id-type="pmid">36268709</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Wang N, Wang W, Wang X, Mang G, Chen J, Yan X, et al. Histone Lactylation Boosts Reparative Gene Activation Post-Myocardial Infarction. Circ Res. 2022;131:893&#x02013;908.<pub-id pub-id-type="pmid">36268709</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Quan</surname><given-names>G</given-names></name><etal/></person-group><article-title>LINC00941 promotes pancreatic cancer malignancy by interacting with ANXA2 and suppressing NEDD4L-mediated degradation of ANXA2</article-title><source>Cell Death Dis</source><year>2022</year><volume>13</volume><fpage>718</fpage><pub-id pub-id-type="doi">10.1038/s41419-022-05172-2</pub-id><pub-id pub-id-type="pmid">35977942</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Wang J, He Z, Liu X, Xu J, Jiang X, Quan G, et al. LINC00941 promotes pancreatic cancer malignancy by interacting with ANXA2 and suppressing NEDD4L-mediated degradation of ANXA2. Cell Death Dis. 2022;13:718.<pub-id pub-id-type="pmid">35977942</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>Z</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Yao</surname><given-names>L</given-names></name><etal/></person-group><article-title>Calponin 1 increases cancer-associated fibroblasts-mediated matrix stiffness to promote chemoresistance in gastric cancer</article-title><source>Matrix Biol</source><year>2023</year><volume>115</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.matbio.2022.11.005</pub-id><pub-id pub-id-type="pmid">36423735</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Lu Y, Jin Z, Hou J, Wu X, Yu Z, Yao L, et al. Calponin 1 increases cancer-associated fibroblasts-mediated matrix stiffness to promote chemoresistance in gastric cancer. Matrix Biol. 2023;115:1&#x02013;15.<pub-id pub-id-type="pmid">36423735</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Jiang</surname><given-names>K</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name></person-group><article-title>PINCH-1 promotes IGF-1 receptor expression and skin cancer progression through inhibition of the GRB10-NEDD4 complex</article-title><source>Theranostics</source><year>2022</year><volume>12</volume><fpage>2613</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.7150/thno.70744</pub-id><pub-id pub-id-type="pmid">35401828</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Wang X, Wang R, Jiang K, Zhu M, Guo L, Wu C. PINCH-1 promotes IGF-1 receptor expression and skin cancer progression through inhibition of the GRB10-NEDD4 complex. Theranostics. 2022;12:2613&#x02013;30.<pub-id pub-id-type="pmid">35401828</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>A</given-names></name></person-group><article-title>NEDD4 E3 ubiquitin ligases: Promising biomarkers and therapeutic targets for cancer</article-title><source>Biochem Pharmacol</source><year>2023</year><volume>214</volume><fpage>115641</fpage><pub-id pub-id-type="doi">10.1016/j.bcp.2023.115641</pub-id><pub-id pub-id-type="pmid">37307883</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Tian X, Chen Y, Peng Z, Lin Q, Sun A. NEDD4 E3 ubiquitin ligases: Promising biomarkers and therapeutic targets for cancer. Biochem Pharmacol. 2023;214:115641.<pub-id pub-id-type="pmid">37307883</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Sarwar</surname><given-names>MS</given-names></name><name><surname>Chou</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><etal/></person-group><article-title>PTEN-knockout regulates metabolic rewiring and epigenetic reprogramming in prostate cancer and chemoprevention by triterpenoid ursolic acid</article-title><source>Faseb j</source><year>2022</year><volume>36</volume><fpage>e22626</fpage><pub-id pub-id-type="doi">10.1096/fj.202201195R</pub-id><pub-id pub-id-type="pmid">36305462</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Wang L, Wang C, Sarwar MS, Chou P, Wang Y, Su X, et al. PTEN-knockout regulates metabolic rewiring and epigenetic reprogramming in prostate cancer and chemoprevention by triterpenoid ursolic acid. Faseb j. 2022;36:e22626.<pub-id pub-id-type="pmid">36305462</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>